CA2181570C - Metalloproteinase inhibitors - Google Patents

Metalloproteinase inhibitors Download PDF

Info

Publication number
CA2181570C
CA2181570C CA002181570A CA2181570A CA2181570C CA 2181570 C CA2181570 C CA 2181570C CA 002181570 A CA002181570 A CA 002181570A CA 2181570 A CA2181570 A CA 2181570A CA 2181570 C CA2181570 C CA 2181570C
Authority
CA
Canada
Prior art keywords
acid
propylcarbamoyl
dimethyl
methyl
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002181570A
Other languages
French (fr)
Other versions
CA2181570A1 (en
Inventor
Raymond Paul Beckett
Mark Whittaker
Andrew Miller
Fionna Mitchell Martin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vernalis R&D Ltd
Original Assignee
Vernalis Oxford Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9401034A external-priority patent/GB9401034D0/en
Priority claimed from GB9415619A external-priority patent/GB9415619D0/en
Application filed by Vernalis Oxford Ltd filed Critical Vernalis Oxford Ltd
Priority claimed from PCT/GB1995/000111 external-priority patent/WO1995019956A1/en
Publication of CA2181570A1 publication Critical patent/CA2181570A1/en
Application granted granted Critical
Publication of CA2181570C publication Critical patent/CA2181570C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Matrix metalloproteinase inhibiting compounds of formula (I), wherein X is a - CO2H or -CONHOH group; R4 is a phenyl or 5- or 6-membered heteroaryl ring wherein any ring nitrogen atom may be oxidised as an N-oxide, which may be optionally fused to a benzene ring or to a 5-, 6- or 7-membered heterocyclic ring, and wherein any of the rings may be optionally substituted.

Description

WO 95/19956 1 ~ ~ ~ PCT/GB95/00111 IMetalloproteinase Inhibitors The present invention relates to therapeutically active hydroxamic acid and carboxylic acid derivative:>, to processes for their preparation, to pharmaceutical compositions containing them, and to the use of such compounds in medicine. In particular, the compounds are inhibitors of metalloproteinases involved in tissue degradation, and in addition are inhibitors of the release of tumour necrosis factor from cells.
background to the Inventi~
Compounds which have the property of inhibiting the action of metalloproteinases involved in connective tissue bre<3kdown such as collagenase, stromelysin and gelatinase (known as "matrix metalloproteinases". and herein referred to as MMPs) are thought to be ~cotentially useful for the treatment or prophylaxis of conditions involving such tissue breakdown, for example rheumatoid arthritis, osteoarthritis, osteopenias such as osteoporosis, periodontitis, gingivitis, corneal epidermal or gastric ulceration, and tumour metastasis, invasion and growth.
MMP
inhibitors are also of potential value in the treatment of neuroinflammatory disorders, including those involving myelin degradation, for example multiple sclerosis, as well as in the manac,~ement of angiogenesis dependent diseases, which include arthritic conditions .and solid tumour growth as well as psoriasis, proliferative retinopathies" neovascular glaucoma, ocular tumours, angiofibromas and hemangiomas. However, the relative contributions of individual MMPs in any of the above disease statE~s is not yet fully understood.
Metalloproteinases are characterised by the presence in the structure of a zinc(//) ionic site. It is now known that there exists a range of metalloproteinase enzymes that includes fibroblast collagenase (Type 1 ), PMN-collagenase, 72 kDa-gelatinase, 92 kDa-gelatinase, stromelysin, stromelysin-2 and PUMP-1 (J.F.
Woessner, FASEB J, 1991, 5, 21 ~45-2154). Many known MMP inhibitors are peptide derivatives, based on naturally occuring amino acids, and are analogues of the cleavage site in the collagen molecule. A recent paper by Chapman et.
al. (J.
2 '~ PCT~GB95100111 Med. Chem. 1993, 36, 4293-43U1 ) reports some general structure/activity findings in a series of N-carboxyalkyl peptides. Other known MMP inhibitors are less peptidic in structure, ands may more properly be viewed as pseudopeptides or peptide mimetics. Such compounds usually have a functional group capable of binding to the zinc (II) site in the MMP,-and known classes include those in which the zinc binding group is a hydroxamic acid, carboxylic acid, sulphydryl, and oxygenated phosphorus (eg phosphinic acid and phosphonamidate including aminophosphonic acid) groups.
Two known classes of paeudopeptide or peptide mimetic MMP inhibitors have a hydroxamic acid group and a carboxylic group respectively as their zinc binding groups. With a few exceptions. such known MMPs may be represented by the structural formula (I) O R, Ra I
R. ~ N _Rs (I) NH
O
Ri \X
in which X is the zinc binding hydroxamic acid (-CONHOH) or carboxylic acid (-COOH) group and the groups R~ to R5 are variable in accordance with the specific prior art disclosures of such compounds. Examples of patent publications disclosing such structurE~s are given below.
In such compounds, it is generally understood in the art that variation of the zinc binding group and the substituents R~, R2 and R3 can have an appreciable effect on the relative inhibition of i:he metalloproteinase enzymes. The group X is thought to interact with metalloproteinase Enzymes by binding to a zinc(II) ion in the active site. Generally the hydroxamic acid group is preferred over the carboxylic acid group in terms of inhibitory activity against the various metalloproteinase enzymes.
However, the carboxylic acid group in combination with other substituents can provide selective inhibition of gelatinase (EP-489,577-A). The R~, RZ and R3 groups W0 95/19956 PCT~GB95/00111 are believed to occupy rs~spectively the Pt , P1' and P2' amino acid side chain binding sites for the natural enzyme substrate. There is evidence that a larger R~
substituent can enhance activity against stromelysin, and that a (C~-C6)alkyl group (such as iso-butyl) at R2 may be preferred for activity against collagenase whilst a phenylalkyl group (such as phenylpropyl) at R2 may provide selectivity for gelatinase over the other metalloproteinases.
Tumour necrosis factor (herein rEaferred to as 'TNF") is a cytokine which is produced initially as a cell-associated 28kD precursor. It is released as an active, l7kD form, which can mE~diate a large number of deleterious effects in vivo.
When administered to animals or humans it causes inflammation, fever, cardiovascular effects, haemorrhage, coagulation and acute phase responses, similar to those seen during acute infections and shock states. Chronic administration can also cause cachexia and anorexia. Accumulation of excessive TNF can be lethal.
There is considerable evidence from animal model studies that blocking the effects of TNF with specific antibodies can be beneficial in acute infections, shock states, graft versus host reactions and autoimmune disease. TNF is also an autocrine growth factor for some rr~yeloma.s and lymphomas and can act to inhibit normal haematopoiesis in patients with these tumours.
Compounds which inhibit the production or action of TNF are therefore thought to be potentially useful for the treatment or prophylaxis of many inflammatory, infectious, immunological or malignant diseases. These include, but are not restricted to, septic shock, haemodynamic shock and sepsis syndrome, post ischaemic reperfusion injury, malaria, Crohn's disease, mycobacterial infection, meningitis, psoriasis, congestive heart failure, fibrotic disease, cachexia, graft rejection, cancer, autoimmune disease, rheumatoid arthritis, multiple sclerosis, radiation damage, toxicity following administration of immunosuppressive monoclonal antibodies such as t'KT3 or CAMPATH-1 and hyperoxic alveolar injury.

WO 95J19956 . PCTJGB95J00111 Since excessive TNF production has been noted in several diseases or conditions also characterised by MPvIP-mediated tissue degradation, compounds which inhibit both MMPs and TNF production may have particular advantages in the treatment or prophylaxis of diseases or conditions in which both mechanisms are involved.
Recently, WO 93/20047 disclosed a class of hydroxamic acid based MMP
inhibitors which also are active in inhibiting TNF production.
As mentioned above, MAP inhibitors have been proposed with hydroxamic acid or carboxylic acid zinc binding groups. The following patent publications disclose hydroxamic acid-based P,AMP inhibitors:
US 4599361 (Searle) EP-A-0236872 (Roche) EP-A-0274453 (Bellon) WO 90/05716 (British Bio-technology) WO 90/05719 (British Bio-technology) WO 91/02716 (British Bio-technology) EP-A-0489577 (Celltech) EP-A-0489579 (Celltech) EP-A-0497192 (Roche) WO 92/13831 (British Bio-technology) WO 92/17460 (SmithKline Beecham) WO 92/22523 (Ress~arch Corporation Technologies) WO 93/09090 (Yam:anouchi) WO 93/09097 (SanN;yo) WO 93/20047 (British Bio-technology) WO 93/24449 (Celltech) 5 (Celltech) EP-A-0574758 (Roche) 6 ~ . PCT~GB95100111 The following patent publications disclose carboxylic acid-based MMP
inhibitors:
EP-A-0489577 (Cellt~ech) EP-A-0489579 (Cellt~ech) WO 93/24449 (Cellt~ech) WO 93124475 (Cellt~ech) Brief DescrirJtion of the Inv n i n This invention is based on the finding that in compounds of formula (I) above wherein X is a hydroxamic acid or carboxylic acid group, an aromatic or heteroaryl R4 substituent has in general thE~ unexpected and desirable effect of increasing activity against stromely;>in relative to compounds of otherwise similar structure but with the usual R4 substituents, while maintaining activity against collagenase and gelatinase. This finding leads to compounds that are broad spectrum inhibitors of the known metalloproteinases. 'The class of compounds of the invention also includes compounds in which the ability to inhibit TNF production is improved relative to compounds of otherwise similar structure but with the usual R4 substituents. The class also includes compounds which are orally bioavailable.
In general, metalloproteinase inhibitors known in the art to possess good activity against stromelysin are compounds such as BB-94 (WO 90/05719 Example 2) that possess relatively large substituents at R~. However, BB-94 and compounds with large substituents at R~ tend to be less bioavailable when dosed orally than compounds with smaller or no R~,~ substituent. A particular advantage of the compounds of the present invention is that the combination of an aromatic or heteroaryl R4 substituent with no R~ substituent or a small R~ substituent can provide oral activity together with broad spectrum activity against the metalloproteinase enzyrnes, including good potency against stromelysin.
The art does not appear to haves recognised the role of an aromatic or heteroaryl R4 substituent in increasing the activity of hydroxamic acid and carboxylic acid based 2-1 ~ 15'~ ~ -pseudopeptide or peptide mimetic MMP inhibitors against stromelysin. Of the publications relating to hydroxamic acid based MMP inhibitors listed above, only WO 93109097 (Sankyo) refer:. to the possibility of a phenyl group in the relevant position. In a structurally different series of MMP inhibitors with phosphinic acid zinc binding groups, WO 93/14112 (Merck) discloses compounds with certain aryl groups in the equivalent position. In neither case is there any comment on the role of that group in the overall stn.rcture/activity relationships of the disclosed compounds. In the field of natural peptide analogues the publication by Chapman et. al. referred to above discloses that aryl groups in the corresponding position to the R4 position of compounds of this invention appear to be preferred for stromelysin activity. V~JO 92121360 (Merck) also discloses natural peptide analogues having certain aryl groups in the corresponding position to the R4 position of ' compounds of this invention. However it is not clear that structure/activity relationships which are true in the field of natural peptide MMP inhibitors will hold true in the field of pseudopeptide or peptide mimetic MMP inhibitors with which this invention is concerned.
Detailed Descri tip on c~f the Invention ___ The present invention provides compounds of general formula I
O R3 Ra RZ N~
H ~ R5 (I) R~ ~X
wherein X is a -COZH or -CONHC>H group;
R, is hydrogen; (C,-CB)alN;yl; (Cz-Cs)alkenyl; phenyl; substituted phenyl;
phenyl A(tlENDED SHEET

WO 95/19956 2181 ~ ~ ~ PCT/GB95/00111 (C~-C6)alkyl); substituted phenyl(C~-C6)alkyl; heterocyclyl; substituted heterocyclyl; heterocyclyl(C~-C6)alkyl; substituted heterocyclyl(C~-C6)alkyl;
a group BSO~A- wherein n is 0, 1 or 2 and B is hydrogen or a (C~-C6) alkyl, phenyl, substituted phenyl, heterocyclyl, (C~-C6)acyl, phenacyl or substituted phenacyl group, and A represents (C~-C6)alkyl; amino; protected amino;
acylamino; OH; SH; (C~-C6)alkoxy; (C~-C6)alkylamino; di-(C~-C6)alkylamino;
(C~-C6)alkylthio; aryl (C~-C6)alkyl; amino(C~-C6)alkyl; hydroxy(C~-Cs)alkyl, mercapto(C~-C6)alkyl or carboxy(C~-C6)alkyl wherein the amino-, hydroxy-, mercapto- or carboxyl-group are optionally protected or the carboxyl- group amidated; lower alkyl sub:;tituted by carbamoyl, mono(lower alkyl)carbamoyl, di(lower ~alkyl)carbamoyl, di(lower alkyl)amino, or carboxy-lower alkanoylamino:
R~ is a (C~-C6)alkyl, (~~2-C6)alkenyl, (C2-C6)alkynyl, phenyl(C~-C6)alkyl, heteroaryt(C~-C6)alkyl, cycloalkyl(C~-C6)alkyl or cycloalkenyl(C~-C6) alkyl group, any one of 'which may be optionally substituted by one or more substituents selected from (C~-C6)alkyl, -O(C~-C6)alkyl, -S(C~-C6)alkyl, halo and cyano (-CN);
R3 is the characterising group of a natural or non-natural a amino acid in which any functional groups may be protected;
Ra is a phenyl or 5- or 6-membered heteroaryl ring wherein any ring nitrogen atom may be oxidi;;ed as an N-oxide, which may be optionally fused to a benzene ring or to a 5-, 6- or 7-membered heterocyclic ring, and wherein any of the rings may be optionally substituted by:
(a) one or more substituents independently selected from hydroxyl, halogen, -CN, -C02H, -C02(C~-C6)alkyl, -(C~-C6)alkyl-C02(C,-C6)alkyl, -CONH2, -CONH(C~-C6)alkyl, -CON((C~-C6)alkyl)2, -CHO, -CH20H, -(G~-C4)pE~rfluoroalkyl, -O(C~-C6)alkyl, -S(C~-Cs)alkyl, WO 95/19956 2 ~ ~; PCT~GB95/00111 -SO(C~-C6);alkyl, -S02(C~-C6)alkyl, -N02, -NH2, -NH(C~-C6)alkyl, -N((C~-C6)alkyl)2, and -NHCO(C~-C6)alkyl, or (b) a group selected from (C~-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3-C8)cycloalkyl, (C4-Ce)cycloalkenyl, phenyl, benzyl, heteroaryl or heteroarylmethyl any of which groups may be optionally substituted with one or more substituents selected from halogen, hydroxyl, amino, carboxyl, (C;~-C4)perfluoroalkyl, (C~-C6)alkyl, -O(C~-Cs)alkyl or -S(C,-C6)afkyl;
R5 is hydrogen or a (~~~-C6)alkyl group;
or a salt, hydrate or solv~ite therE~of.
As used herein the term "(C~-C6)alkyl" or "lower alkyl" means a straight or branched chain alkyl moiety having from 1 to 6 carbon atoms, including for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, pentyl and hexyl.
The term "(C2-C6)alkenyl" means a straight or branched chain alkenyl moiety having from 2 to 6 carbon atoms and having in addition one double bond of either E or Z stereochemistry vvhere applicable. This term would include, for example, vinyl, t-propenyl, 1- andl 2-butenyl and 2-methyl-2-propenyl.
The term "cycloalkyl" mE~ans a saturated alicyclic moiety having from 3-8 carbon atoms and includes, for example, cyclohexyl, cyclooctyl, cycloheptyl, cyclopentyl, cyclobutyl and cyclopropyl.
The term "cycloalkenyl" means an unsaturated alicyclic moiety having from 3-8 carbon atoms and inclu~jes, for example, cyclohexenyl, cyclooctenyl, cycloheptenyl, cyclopentenyl, cyclobutenyl and cyclopropenyl. In the case of cycloalkenyl rings of from 5-8 carbon atoms, the ring may contain more than one double bond.

WO 95/19956 ~ PCTIGB95l00111 The unqualified term "heterocyclyl" or °heterocyclic" means (i) a 5-7 membered heterocyclic ring containing one or more heteroatoms selected from S, N and O, and optionally fused to a benzene ring, including for example, pyrrolyl, furyl, thienyl, imidazolyl, oxazolyl, thiazolyl, thiadiazolyl, pyrazolyl, pyridinyl, pyrrolidinyl, pyrimidinyl, morpholinyl, piperazinyl, indolyl, benzimidazolyl, maleimido, succinimido, phthalimido, 1,2-dinnethyl-3,5-dioxo-1,2,4-triazolidin-4-yl, 3-methyl-2,5-dioxo-1-imidazolidinyl and 3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl, or (ii) a naphththalimido (ie 1,3-dihydro-1,3-dioxo-2H-benz[fJisoindol-2-yl), 1,3-dihydro-1-oxo-2H-bent[fJisoindol-2-yl, 1,3-dihydro-1,3-dioxo-2H-pyrrolo[3,4-b]quinolin-2-yl, or 2,3-dihydro-1,3-dioxo-1 H-bent[d,e]isoquinolin-2-yl group.
The term "5- or 6-membered heterocyclic ring" means such rings having 5 or 6 atoms in the ring, wherein the heteroatom(s) may be one or more nitrogen.
oxygen or sulphur atoms, and includes heterocycles containing nitrogen, oxygen, or sulphur alone or containing two nitrogen atoms, a nitrogen and an oxygen atom, a nitrogen and a sulphur atom, two nitrogen atoms and an oxygen atom, two nitrogen atoms and a sulphur.
The "heteroaryl" means a 5-7 membered substituted or unsubstituted aromatic heterocycle containing one or more heteroatoms. Illustrative of such rings are thienyl, furyl, pyrrolyl, imidazolyl, thiazolyl, pyrazolyl, isoxazolyl, isothiazolyl, trizolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl and triazinyl.
Unless otherwise specified in the context in which it occurs, the term "substituted"
as applied to any moiety herein means substituted with up to four substituents, each of which independently may be (C~-C6)alkoxy, hydroxy, mercapto, (C~-C6)alkylthio, amino, halo (including fluoro, chloro, bromo and iodo), trifluoromethyl, vitro, -COOH, -CONH2 or -CONHRA wherein RA is a (C~-C6)alkyl group or the residue of a natural alpha-amino acid.
The term "characteristic side chain of a natural alpha-amino acid" means the WO 95119956 ~ PCT/GB95I00111 - _ characteristic side chain attached to the -CH(NH2)(COOH) moiety in the following amino acids: glycine, ala.nine, valine, leucine, isoleucine, phenylalanine, tyrosine, tryptophan, serine, threonine, cysteine, methionine, asparagine, glutamine, lysine, histidine, arginine, glutamic acid and aspartic acid.
Natural alpha-amino acids which contain functional substituents, for example amino, carboxyl, hydroxy, mercapto, guanidyl, imidazolyl, or indolyl groups in their characteristic side chains include arginine, lysine, glutamic acid, aspartic acid, tryptophan, histidine, ser~,ine, thre~onine, tyrosine, and cysteine. When R3 in the compounds of the invention is one of those side chains, the functional substituent may optionally be protected.
The term "protected" whE~n used in relation to a functional substituent in a side chain of a natural alpha-,amino acid means a derivative of such a substituent which is substantially non-functional. Ins this context, protected amino groups include amido and acylamino, protected hydroxy or mercapto groups include ethers and thioethers, protected carboxyl groups include esters, and imidazolyl, indolyl or guanidyl groups may be protected as t-butoxycarbonyl derivatives. These are only examples of the many protecting derivatives known in the art, and others will be known to the skilled man.
Salts of the compounds of the invention include physiologically acceptable acid addition salts for example hydrochlorides, hydrobromides, sulphates, methane sulphonates, p-toluenesulphonates, phosphates, acetates, citrates, succinates, lactates, tartrates, fumarates and maleates. Salts may also be formed with bases, for example sodium, potassium, magnesium, and calcium salts.
There are several chiral centres in the compounds according to the invention because of the presence of asymmetric carbon atoms. The presence of several asymmetric carbon atoms gives rise to a number of diastereomers with R or S
stereochemistry at each chiral centre. General formula (I), and (unless specified otherwise) all other formulae in i:his specification are to be understood to include all.

such stereoisomers and mixtures (for example racemic mixtures) thereof.
In the compounds of the invention, the preferred stereochemistry is in general as follows:
C atom carrying the R~ and X groups - S, C atom carrying the R2 group - R, C atom carrying the R3 group - S, but mixtures in which th~a above configurations predominate are also contemplated.
As previously stated, the compounds of the invention are principally distinguished from the compounds disclosed in the prior art patent publications listed above by the identity of the group 1~4. Accordingly, the groups R~, R2, R3, and RS may be any of the groups which have been disclosed in the corresponding positions of compounds disclosed in any of those prior art patent publications listed above.
Without limiting the genE~rality of the foregoing, the following classes of substituent R3 have been disclosed in the corresponding position of prior art compounds, and are therefore suitable R~, groups for use in compounds of the present invention:
(C~-C6)alkyl, benzyl, hydroxybenzyl, benzyloxybenzyl, (Ci-C6)alkoxybenzyl, or benzyloxy(C~-C6)alkyl group; and the characterisincl group of a natural a amino acid, in which any functional group may be protected, any amino group may be acylated and any carboxyl group present may be amidated; and a group -[AIkj~Rs where Alk is a (C~-C6)alkyl or (C2-C6)alkenyl group optionally interrupted by one or more -O-, or -S- atoms or -N(R~)- groups [where R~ is a hydrogen atom or a (C~-C6)alkyl group], n is 0 or 1, and R6 is an optionally substituted cycloalkyl or cycloalkenyl group; and a benzyl group substituted in the phenyl ring .by a group of formula WO 95!19956 ~ .~ PCTIGB95/00111 -OCH2COR8 where R8 is hydroxyl, amino, (C~-C6)alkoxy, phenyl(C,-Cs)alkoxy, (C~-C6)alkylamino, di((C~-C6)alkyl)amino, phenyl(Ci-C6)alkylamino, the residuE~ of an amino acid or acid halide, ester or amide derivative thereof, said residue being linked via an amide bond, said amino acid being selected from glycine, a or ~i alanine, valine, leucine, isoleucine, phenylalanine, tyrosine, tryptophan, serine, threonine, cysteine, methionine, asparagine, glutarnine, ly;>ine, histidine, arginine, glutamic acid, and aspartic acid; and a heterocyclic((C~-C6)alkyl group, either being unsubstituted or mono- or di-substituted in the ~heterocyclic ring with halo, vitro, carboxy, (C~-C6)alkoxy, cyano, (C,-C6)alkanoyl. trifluoromethyl (C~-C6)alkyl, hydroxy, formyl, amino, (C~-C6)alkylamino, di-(C~~~C6)alkylamino, mercapto, (C~-C6)alkylthio, hydroxy(C~-C6)al~;yl, merc:apto{C~-C6)alkyl or (C~-C6)alkylphenylmethyl;
R3 may also be a group -CRaRbIR~ in which:
each of Ra, Rb and R~ is independently hydrogen, (C~-C6)alkyl, (C2-C6)alkenyl, (C2-C,;)alkynyl, phenyl(C~-C6)alkyl, (C3-C8)cycloalkyl, the foregoing being subject to~ the proviso that Ra, Rb and R~ are not all hydrogen; or R~ is hydrogen, (C~-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, phenyl(C~-C6)alkyl, or (C3-C,3)cycloalkyl, and Ra and Rb together with the carbon atom to which they are attached form a 3 to 8 membered cycloalkyl or a 5- to 6-membered hetero~cyclic ring; or Ra, Rb and R~ together with the carbon atom to which they are attached form a tricyclic ring (for example adamantyl); or Ra and Rb are each independently (C~-C6)alkyl, (C2-C6)alkenyl, (C2-WO 95/19956 . _ . PCT/GB95/00111 C6)alkynyl, phenyl(C~-C6)alkyl, or a group as defined for R~ below other than hydrogen, or Ra and Rb together with the carbon atom to which they are attached form a 3 to 8 membered cycloalkyl or a 3- to 8-membered heterocyclic ring, and R~ is hydrogen, -OH, -SH, halogen, -CN, -C02H, (C~-C4)perfluoroalkyl, -CH20H, -C02(C~-C6)alkyl, -O(C~-C6)alkyl, -O(C2-C6)alkenyl, -S(C~-C6)alkyl, -SO(C~-Cs)alkyl, -S02(C~-C6) alkyl, -S(C2-C6)alkenyl, -SO(C2-C6)alf;enyl, -S02(C2-C6)alkenyl or a group -C~-W wherein C~ represents a bond or -O-, -S-, -SO- or -S02- and W represents a phenyl, phenylalkyl, (C3-C8)cycloalkyl, (C3-Ca)cycloalkylalkyl, (C4-Ce)cycloalkenyl, (C4-C8)cycloalkenylalkyl, heteroaryl or heteroarylalkyl group, which group W
may optionally be substituted by one or more substituents independently selected from, hydroxyl, halogen. -CN, -C02H, -C02(C~-C6)alkyl, -CONH2, -CONH(C,-C6)alkyl, -CONH(C,-C~alkyl)2, -CHO, -CH20H. (C~-C4)perfluoroalkyl, -O(C1-C;6)alkyl, -S(C~-Cs)alkyl, -SO(C~-C6)alkyi, -S02(C~-C6)alkyl, -NOZ, -NH2, -NH(C~-C6)alkyl, -N((C~-C6)alkyl)2, -NHCO(C~-C6)alkyl, (C~-C6)alkyl, (C2-t~s)alkenyl, (C2-C6)alkynyl, (C3-C8)cycloalkyl, (C4-C8)cycloalkenyl, phenyl or benzyl.
More specifically with respect to the groups R~, R2, R3, R4 and R5 in compounds of the invention:
Examples of particular R~ groups include hydrogen, methyl, ethyl, hydroxyl, allyl, thienylsulphanylmetlhyl, thienylsulphinylmethyl, thienylsulphonylmethyl and phthalimidomethyl. Presently preferred are compounds in which R~ is hydrogen, hydroxyl, allyl or phthalimidomethyl.
Examples of particular R2 groups include iso-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n~-decyl, cyclohexylpropyl, phenylpropyl, 4-chlorophenylpropyl, 4-methylphenylpropyl, 4-methoxyphenylpropyl, phenylbutyl, propyloxymethyl and propylsulphanyl. Presently preferred are compounds in whiich R2 is isobutyl, n-heptyl, or phenylpropyl.

WO 95/19956 ~ ~ ~ ,, PCTIGB95/00111 '""' Examples of particular R3 groups include benzyl, iso-butyl or t-butyl, 1-benzylthio-1-methylethyl, and 1-mercapto-1-methylethyl. Presently preferred are compounds in which R3 is t-butyl or 1-mercapto-1-methylethyl.
Examples of R4 groups include optionally substituted phenyl, napthyl, furanyl, thienyl, pyrrolinyl, tetrahydrofuranyl, imidazolyl, oxadiazolyl, thiazolyl, thiadiazolyl, pyridinyl, pyridinyl N-oxides, piperazinyl, indolyl, benzimidazolyl, benzotriazolyl, pyrazinyl, pyridazinyl, pyrimidinyl, dithianyl, benzo[b]thienyl, isoxazolyl or quinolinyl. Examples of particular R4 groups include phenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 3,4-dimethoxyphenyl, 2-fluorophenyl. 3-fluorophenyl, 4-fluorophenyl, 2-chlorophenyl. 3-ciilorophenyl, 4-chlorophenyl, 3,4-dichlorophenyl, 3.5-dichlorophenyl, 2-bromophenyl. 3-bromophenyl, 4-bromophenyl, 2-iodophenyl, 3-iodophenyl, 4-iodophenyl, 2-methylphenyl. 3-methylphenyl, 4-methylphenyl, 3,4-dimethyl, 2-t-butylphenyl, 3-t-butylphenyl, 4-t-butylphenyl, 4-t-butyl-2,6-dimethylphenyl, 2-nitrophenyl, 3-nitrophenyl, 4-nitrophenyl, 2-cyanophenyl, 3-cyanophe~nyl, 4-cyanophenyl, 2-acetylphenyl, 3-acetylphenyl, 4-ac;etylphenyl, 2-methylsulphonylphenyl, 3-methylsulphonylphenyl, 4-methylsulphonylphenyl, 2-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 3,5-ditrifluoromethylphenyl, 2-aminophenyl, 3-aminophenyl, 4-aminophenyl, 2-N,N-dimethylaminophE~nyl, 3-N,N-dimethylaminophenyl, 4-N,N-dimethylaminophE~nyl, 2-hydroxyphenyl, 3-hydroxyphenyl, 4-hydroxyphenyl, 2-napthyl, furan-2-yl, thien-2-yl, pyrrol-2-yl, tetrahydrofuran-2-yl, imidazol-yl, thiazol-2-yl, 4-ethoxycarbonylmethylthiazol-2-yl, 4-phenylthiazol-2-yl, 4,5-dimethylthiazol-2-yl, 5-bromothiazol-2-yl, 4-Pert-butylthiazol-2-yl, benzothiazol-2-yl, 1,2,4-oxadiazol-5-yl, 3-methyl-1,2,4-oxadiazol-5-yl , 3-phenyl-1,2,4-oxadiazol-5-yl, 1,2,4-oxadiazol-3-yl, 1,3,4-oxadiazol-2-yl, 1,2,4-thiadiazol-5-yl, 3-phenyl-1i ,2,4-thiadiazol-5-yl, 1,3,4-thiadiazol-2-yl, 5-methyl-1,3,4-thiadiazol-2-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, N-oxides of pyridin-2-yl pyridin-3-yl and pyridin-4-yl, piperazin-1-yl, indol-2-yl, benzimidazol-2-yl, benzotriazol-2-yl, pyrazin-2-yl, 1,2-pyridazin-3-yl, 1,3-pyrimidin-5-yl, 1,3-dithian-2-yl, benzo[b]thien-2-yl, isoxazol-5-yl, quinolin-yl. In general, compounds wherein R4 is a thiazolyl or substituted thiazolyl group are preferred for their activity in inhibiting the release of TNF.
Presently preferred! are compounds in which R4 is phenyl, 3-methoxyphenyl, pyridin-2-yl, pyridin-3-yl, and thiazol-2-yl, 4,5-dimethylthiazol-2-yl, 5-bromothiazol-2-yl, 4-ethoxycarbonytmethylthiazol-2-yl, 5-methyl-1,3,4-thiadiazol-2-yl or 4-terlbutylthiazol-2-yl. Particularly preferred at present are compounds wherein R4 is 3-methoxyphenyl, pyridin-2-yl, pyridin-3-yl, thiazol-2-yl, 4-ethoxycarbonylmethylthiazol-2-yl, 5-methyl-1,3,4-thiadiazol-2-yl and 4-tert-butylthiazol-2-yl.
Examples of particular RS groups include hydrogen, methyl and ethyl.
Presently preferred are compounds in which RS is hydrogen.
Compounds of the present invention which are currently preferred for their combination of high intrin;>ic activity and good bioavailability when administered orally are:
3R-(2,2-Dimethyl-1 S-pyridin-2-ylcarbamoyl-propylcarbamoyl)-5-methyl-2S-propen-2-yl-hexanohydroxamic acid, 3R-(2,2-Dimethyl-1 S-pyridin-2-ylcarbamoyl-propylcarbamoyl)-2S-hydroxy-5-methylhexanohydroxamic acid, 3R-(2,2-Dimethyl-1 S-(5-mE~thyl-1,3,4-thiadiazol-2-ylcarbamoyl)-propylcarbamoyl)-2S-hydroxy-5-methylhexanohydroxamic acid, 3R-(2,2-Dimethyl-1 S-(3-methoxyphenyl)carbamoyl-propylcarbamoyl)-2S-hydroxy-5-methylhE~xanohydroxamic acid, 3R-(2,2-Dimethyl-1 S-pyridin-3-ylcarbamoyl-propylcarbamoyl)-2S-hydroxy-5-methylhexanohydroxamic acid and 3R-(2,2-Dimethyl-1 S-pyridin-2-ylcarbamoyl-propylcarbamoyl)-5-methyl-2S-phthalimidomethylhexanohydroxamic acid, and salts, solvates or hydrates thereof.
Compounds of the present invention which are currently preferred for their activity in inhibiting TNF releasE~ are:
3R-(2,2-Dimethyl-1 S-(thiazol-2-ylcarbamoyl)-propylcarbamoyl)-5-methyl-2S-propen-2-yl-hexanohydroxamic acid, 3R-(2.2-Dimethy~-1 S-(thiazol-2-ylcarbamoyl)-propylcarbamoyl)-2S-hydroxy-5-methylhexanohydroxarnic acid, and 3R-(2,2-Dimethyl-1 S-(4-ethoxycarbonylmethylthiazol-2-ylcarbamoyl)-propylcarbamoyl;I-2S-hyciroxy-5-methylhexanohydroxamic acid, and salts, solvates or hydrates thereof.
Further specific compounds of the invention are:
5-Methyl-3R-(2-phenyl-1 S-phenylcarbamoyl-ethylcarbamoyl)-hexanohydroxamic acid, 3R-{2,2-Dimethyl-1 S-phenylcarbamoyl-propylcarbamoyl)-5-methyl-hexanohydroxamic acid, 3R-(2,2-Dimethyl-1 S-pyridin-2-ylcarbamoyl-propylcarbamoyl)-5-methyl-hexanohydroxamic acid, WO 95119956 ~ PCT/GB95100111 3R-(2,2-Dimethyl-1 S-phenylcarbamoyl-propylcarbamoyl)-2S-hydroxy-5-methylhexanohydroxamic acid, 2S-Hydroxy-3R-(;3-methyl-1 S-napth-2-ylcarbamoyl-butylcarbamoyl)-5-methyl-hexanohydroxamic acid-2S-Hydroxy-3R-(a-methyl-1 S-(4-methoxyphenyl)carbamoyl-butylcarbamoyl)-5-methyl-hexanohydroxamic acid, 3R-(2,2-Dimethyl-1 S-(4-fe~rtbutyl-2,6-dimethylphenyl)carbamoyl-propylcarbamoyl)-2S-hydroxy-5-methylhexanohydroxamic acid, 3R-(2,2-Dimethyl-1 S-(4-methoxyphenyl)carbamoyl-propylcarbamoyl)-2S-hydroxy-5-methylhexanoh~ydroxamic acid, 3R-(2,2-Dimethyl-1 S-pyridin-4-ylcarbamoyl-propylcarbamoyl)-2S-hydroxy-5-methylhexanohydroxamic acid, 3R-(2,2-Dimethyl-1 S-(4-hydroxyphenyl)carbamoyl-propylcarbamoyl)-2S-hydroxy-5-methylhexanohydroxamic acid, 3R-(2-Benzylthio-;?-methyl-1 S-(pyridin-2-ylcarbamoyl)propylcarbamoyl)-2S-hydroxy-5-methylhexanohydroxamic acid, 3R-(2,2-Dimethyl-1 S-phenylcarbamoyl-propylcarbamoyl)-2S-hydroxy-5-phenylhexanohydroxamic acid, 3R-(2,2-Dimethyl-1 S-(4,5-dimethylthiazol-2-ylcarbamoyl)-propylcarbamoyl)-2S-hydroxy-5-methylhexanohydroxamic acid, 3R-(2,2-Dimethyl-1 S-(5-bromo-thiazol-2-ylcarbamoyl)-propylcarbamoyl)-2S-hydroxy-5-methylhexanohydroxamic acid, PCT/GB9s/00111 " ' wo 9sn~s6 3R-(2,2-Dimethyl~-1 S-{4-phenyl-thiazol-2-ylcarbamoyl)-propylcarbamoyl)-2S-hydroxy-5-methylhexanohydroxamic acid, 3R-(2,2-Dimethyl-~1 S-(4-t,ert-butylthiadiazol-2-ylcarbamoyl)-propylcarbamoyl)-2S-hydroxy-5-methylhexanohydroxamic acid, 3R-{2,2-Dimethyl-1 S-phenylcarbamoyl-propylcarbamoyl)-5-methyl-2S-propen-2-yl-hexanohydroxamic acid, 3R-(2,2-Dimethyl-~1 S-(4-nnethoxyphenylcarbamoyl)-propylcarbamoyl)-5-methyl-2S-propen-2-yl-hE~xanohydroxamic acid, 3R-(2-Benzylthio-2-methyl-1 S-(pyridin-2-ylcarbamoyl)-propylcarbamoyl)-5-methyl-2S-propen-2-yl-hexanohydroxamic acid, 3R-(2,2-Dimethyl-~1 S-(pyridin-3-ylcarbamoyl)-propylcarbamoyl)-5-methyl-2S-propen-2-yl-hexanohydroxamic acid, 3R-(2,2-Dimethyl-~1 S-(4-hydroxyphenylcarbamoyl)-propylcarbamoyl)-5-methyl-2S-propen-2-yl-hE~xanohydroxamic acid, 3R-(2,2-Dimethyl-1 S-(3-methoxyphenylcarbamoyl)-propylcarbamoyl)-5-methyl-2S-propen-2-yl-hErxanohydroxamic acid, 3R-(2,2-Dimethyl-1 S-(pyridin-4-ylcarbamoyl)-propylcarbamoyl)-5-methyl-2S-propen-2-yl-hE~xanohydroxamic acid, 3R-(2,2-Dimethyl-1 S-(2-methoxyphenylcarbamoyl)-propylcarbamoyl)-5-methyl-2S-thien-2-ylsulfanylmethyl-hexanohydroxamic acid, 3R-(2,2-Dimethyl-1 S-(pyridin-2-ylcarbamoyl)-propylcarbamoyl)-5-methyl-WO 95/19956 ~ PCTlGB95100111 2S-thien-2-ylsulfanylmethyl-hexanohydroxamic acid, 3R-(2,2-Dimethyl-1 S-(2-methoxyphenylcarbamoyl)-propylcarbamoyl)-5-methyl-2S-thien-2-ylsulfinylmethyl-hexanohydroxamic acid, 3R-(2,2-Dimethyl-1 S-(pyridin-2-ylcarbamoyl)-propylcarbamoyl)-5-methyl-2S-thien-2-ylsulfinylmethyl-hexanohydroxamic acid, 3R-(2,2-Dimethyl-1 S-phenylcarbamoyl-propylcarbamoyl)-2S-hydroxy-5-phenylhexanoic acid, 3R-(2,2-Dimethyl-1 S-(N-oxy-pyridin-2-yl)carbamoyl-propylcarbamoyl)-2S-hydroxy-5-methylhexanohydroxamic acid.
and salts, solvates or hydrates thereof.
Compounds according to the present invention in which X is a hydroxamic acid group -CONHOH may beg prepared from corresponding compounds of the invention in which X is a carboxylic acid group -COOH or from the corresponding protected hydroxamic acid derivatives. That process, which forms another aspect of the invention, comprises:
(a) causing an acid of general formula (II) O R, Ri I
R= ~ N-RS (II) NH
O
R~ ~COOH
or an activated derivative thereof to react with hydroxylamine, O-protected hydroxylamine, or an N,O-diprotected hydroxylamine, or a salt thereof, R~, R2, R3, R4, and R5 being as defined in general formula (I) except that any substituents in R, , R2, R3, R4, and RS which are potentially reactive with ~~$~.~~~~ 20 hydroxylamine, O-protected hydroxylamine, the N,O-diprotected hydroxylamine or their salts may themselves be protected from such reaction, then removing any protecting groups from the resultant hydroxamic acid moiety and from any protected substituents in R~, R2, R3, R4, and R5; or (b) deprotecting a diprotected hydroxamic acid derivative of formula (Ilb) O R3 Ra R2 NH N'Rs(Ilb) O
R' O
N
R,,,~ ~O'R,s in which R~, R2, R3, R4, and RS are as defined in general formula (I), Ri4 is an amino protecting group and RCS is a hydroxyl protecting group.
For method (a) conversion of (II) to an activated derivative such as the pentafluorophenyl, hydroxysuccinyl, or hydroxybenzotriazolyl ester may be effected by reaction with the appropriate alcohol in the presence of a dehydrating agent such as dicyclohexyl dicarbodiimide (DCC), N,N-dimethylaminopropyl-N'-ethyl carbodiimide (EDC), or 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline (EEDQ).
Protecting groups as referred to above are well known per se, for example from the techniques of peptide chE~mistry. Amino groups are often protectable by benzyloxycarbonyl, t-butoxycarbo~nyl or acetyl groups, or in the form of a phthalimido group. Hydroxy groups are often protectable as readily cleavable ethers such as the t-butyl or benz:yl ether, or as readily cieavable esters such as the acetate. Carboxy groups are often protectable as readily cleavable esters, such as the t-butyl or benzyl ester.
Examples of O-protected hydroxylamines for use in method (a) above include O-benzylhydroxylamine, O-.4-methoxybenzylhydroxyiamine, O-trimethylsilylhydroxylamine, and O-tert-butoxycarbonylhydroxylamine.
Examples of O,N-diprotecaed hydroxylamines for use in method (a) above include N,O-bis(benzyl)hydroxylamine, N,O-big(4-methoxybenzyl)hydroxylamine, N-tert-butoxycarbonyl-O-tert-butyldimethylsilylhydroxylamine, N-tert-butoxycarbonyl-O-tetrahydropyranylhydroxylamine, and N,O-bis(tert-butoxycarbonyl)hydroxylamine.
For method (b) suitable protectingi groups Ri4 and R~5 are benzyl and substituted benzyl (eg 4-methoxybenzyl). Such protecting groups may be removed by hydrogenolysis, while the 4-methoxybenzyl group may also be removed by acid hydrolysis.
In method (a) in the special case where R~ in compound (I) is hydroxy, a particularly useful technique may be reaction of hydroxylamine with a dioxalone of formula (Ila):
O R, R~
I
R,, N-RS
~fH (I la) O' O
O
R,, -Ri~O
wherein the groups R~2 and R~3 are derived from a dioxalone forming reagent, and may be, for example, hydrogen, alkyl, phenyl or substituted phenyl. The dioxalone ring is opened on reaction with hydroxylamine to give the required hydroxamic acid derivative of formula (I). -Compounds according to the present invention in which X is a carboxylic acid group -COOH may be prepared by a process comprising: coupling an acid of formula (III) or an activated derivative thereof with an amine of formula (IV) PCTlGB95/00111 ~'"

O
R' OH (III) R~ Ny R' (IV) H,N
R, COOR" O
wherein R~ R2, R3, R4, and RS are as defined in general formula (I) except that any substituents in R~, R2, R3, R4, and R5 which are potentially reactive in the coupling reaction may themselves be protected from such reaction, and R> > represents a hydroxy protecting group, and subsequently removing the protecting group R»
and any protecting groups frorn R~ R2, R3, R4, and R5.
Compounds of formula (Ilb) may be prepared by a process comprising: causing an acid of formula (Illa) or an activated derivative thereof to react with an amine of formula (IV) ~OH
(Illa) R~ R~ (IV) O
R~ N _Rs H=N
R~a/N.O_R~s O
wherein R~ R2, R3, R4, and RS are as defined in general formula (I) except that any substituents in R~, R2, R3, R4, and R5 which are potentially reactive in the coupling reaction may themselves be protected from such reaction, R~4 is an amino protecting group and R~5 is a hydroxyl protecting group as referred to in connection with formula (Ilb) above, and subsequently removing any protecting groups from R~
R2, R3, R4, and Rs.
Active derivatives of acid:; (III) and (Illa) include activated esters such as the pentafluorophenyl ester, acid anhydrides and acid halides, eg chlorides.
Suitable hydroxy protecting group:. R» may be selected from those known in the art.
Amine intermediates of formula (IV) are either known compounds or may be prepared from known amino acid starting materials using standard methods and by analogy with the specific ~preparavive examples herein.
In the special case where R~ in compound (III) or (Illa) is hydroxy, it too may be protected during the coupling of compounds (III) or (Illa) and (IV). In the case where R~ is hydroxy in compound (III) a particularly useful technique may be simultaneous protection o~f the two hydroxy groups as a dioxalone of formula (V):

R,, ~
,OH (V) O' ~ O
R1,~~~
Ru wherein the groups R~2 and R~3 are derived from a dioxalone forming reagent, and may be, for example, hydrogen, alkyl, phenyl or substituted phenyl.
As mentioned above, compounds of formula (I) are useful in human or veterinary medicine since they are active as inhibitors of MMPs, and a further advantage lies in their ability to inhibit the release of tumour necrosis factor (TNF) from cells.
Accordingly in another asF~ect, this; invention concerns:
(i) a method of management (by which is meant treatment or prophylaxis) of diseases or conditions mediated by MMPs and/or TNF in mammals, in particular in humans, which method comprises administering to the mammal an effective amount of a compound as defined with respect to formula (I) above, or a WO 95!19956 2181 ~ 7 pharmaceutically acceptable salt thereof; and (ii) a compound as defin~sd with respect to formula (I) for use in human or veterinary medicine, particularly in the management (by which is meant treatment or prophylaxis) of diseases or conditions Tnediated by MMPs and/or TNF; and (iii) the use of a compound as defined with respect to formula (I) in the preparation of an agent for the management (by which is meant treatment or prophylaxis} of diseases or conditions mediated by MMPs and/or TNF.
Diseases or conditions mediated by MMPs include those involving tissue breakdown such as bona resorption, inflammatory and neuroinflammatory diseases, dermatological conditions, solid tumour growth and tumour invasion by secondary metastases, and angiogenesis dependent diseases, in particular rheumatoid arthritis, ostE~oarthritis, periodontitis, gingivitis, corneal ulceration, solid tumour growth and tumour inva:>ion by secondary metastases, neovascular glaucoma, multiple sclerosis, and psoriasis. Diseases or conditions mediated by TNF include inflammation, fever, cardiovascular effects, haemorrhage, coagulation and acute phase responae, cachexia and anorexia, acute infections, shock states, graft versus host reactions and autoimmune disease.
In a further aspect of the invention there is provided a pharmaceutical or veterinary composition comprising .a compound of formula (I) together with a pharmaceutically or veterinarily acceptablE~ excipiE~nt or carrier. Included within this aspect of the invention is a pharmaceutical or veterinary composition comprising a compound of formula (I) together with a pharmaceutically or veterinarily acceptable excipient or carrier, characterised in that the composition is adapted for oral administration.
One or more compounds. of general formula (I) may be present in the composition together with one or more excipient or carrier.
The compounds with which the invention is concerned may be prepared for WO 95119956 c~ PCTlGB95/00111 administration by any route consistent with their pharmacokinetic properties.
The orally administrable comiaosition;s may be in the form of tablets, capsules, powders, granules, lozenges, liquid or gel preparations, such as oral, topical, or sterile parenteral solutions or suspensions. Tablets and capsules for oral administration may be in unit dose presentation form~and may contain conventional excipients such as binding agents, 'for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinyl-pyrrolidone; fillE~rs for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; ta~bletting lubricant, for example magnesium stearate, talc, polyethylene glycol or silica; disintegrants for example potato starch, or acceptable wetting agents such as sodium lauryl sulphate. The tablets may be coated according to methods well known in normal pharmaceutical practice. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions. emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
Such liquid preparations may contain nonventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, glucose syrup, gelatin hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqus~ous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyi p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.
The dosage unit involved in oral .administration may contain from about 1 to 250mg, preferably from about 25 to 250mg of a compound of the invention. A
suitable daily dose for a rnammal may vary widely depending on the condition of the patient. However, a dose of a compound of general formula I of about 0.1 to 300mg/kg body weight, particularly from about 1 to 100mg/kg body weight may be appropriate.
For topical application to l:he skin, the drug may be made up into a cream, lotion or ointment. Cream or ointment formulations which may be used for the drug are WO 95/19956 ~ ~ ~ PCTIGB95I00111 conventional formulations well known in the art, for example as described in standard textbooks of pharmaceutics such as the British Pharmacopoeia.
For topical application to the eye, the drug may be made up into a solution or suspension in a suitable sterile aqueous or non aqueous vehicle. Additives, for instance buffers such as sodium metabisulphite os disodium edeate;
preservatives including bactericidal and fungicidal agents such as phenyl mercuric acetate or nitrate, benzalkonium chloride or chlorhexidine, and thickening agents such as hypromellose may also be included.
The dosage for topical administration will of course depend on the size of the area being treated. For the eyes, each dose may typically be in the range from 10 to 100mg of the drug.
The active ingredient may also be administered parenterally in a sterile medium.
Depending on the vehicle and concentration used, the drug can either be suspended or dissolved in the vehicle. Advantageously, adjuvants such as a local anaesthetic, preservativE~ and buffering agents can be dissolved in the vehicle.
For use in the treatment of rheumatoid arthritis, the drug can be administered by the oral route or by injection intra-articularly into the affected joint. The daily dosage for a 70kg mammal may be in the range 1 Omgs to 1 gram.
The following Examples illustrate embodiments of the invention:
The amino acids used in the examples were commercially available or were prepared according to lit~srature procedures.
The following abbreviations have been used throughout:
DIPE Diisopropyl ether DMF N,N-Dimethylformamide HOBt 1-Hydroxyb~enzotriazole LDA Lithium diisopropylamide mCPBA m-Chlorope~rbenzoic acid NMM N-Methylmorpholine THF Tetrahydrof~uran TFA Trifluoroacetic acid TLC Thin layer chromatography EDC N-Ethyl-N'-(3-dimethylaminopropyl)carbodiimide hydrochloride ~ H and ~3C NMR spectra were recorded using a Bruker AC 250E spectrometer at 250.1 and 62.9 MHz, respectively. Elemental microanalyses were performed by CHN Analysis Ltd. (Alpha House, Countesthorpe Road, South Wigston, Leicester LE8 2PJ, UK) or Medac Ltd. (Department of Chemistry, Brunel University, Uxbridge, Middlesex UB8 3PH).

5-Methyl-3R-(2-phenyl-1:i-phenylcarbamoyl-ethylcarbamoyl)-hexanohydroxamic acid w H '~~~ H NH
y H ~w CONHOH O
T P
N-(4-Methylpentanoyl)-4S.-phenyl methyl-oxazolidin-2-one A dry 500 ml flask equippE~d with a magnetic stirrer was charged with 4S-phenylmethyl-oxazolidin-2-one (1 i'.72 g, 100 mmol), this was capped with a rubber septum and flushed with nitrogen. Anhydrous THF (300 ml) was added via a WO 95119956 ~ ~ ~ ~ ~~ ~ ~ PCTIGB95/00111 cannula and the resulting solution was cooled to -78°C in an acetone/dry-ice bath.
A solution of 1.47 M n-butyllithium in hexane (68.4 ml, 101 mmol) was transferred via cannula to a dry, septum-stoppered 100 ml dropping funnel. This was added dropwise to the THF solution over 10 minutes.
4-Methylvaleric acid chloride (14.80 g, 110 mmol) was added in one portion by syringe after completion of the addition of n-butyllithium. The resulting solution was stirred at -78°C for 30 minutes and then allowed to warm to ambient temperature over 30 minutes. Excess acid chloride was quenched by the addition of aq.
ammonium chloride (60 ml) and the bulk of the solvent was removed under reduced pressure. The resulting slurry was extracted with dichloromethane (2 x ml). The combined organic extracts were washed with 1 M sodium hydroxide (75 ml), brine (75 ml), dried (;anhydrous sodium sulphate) and filtered. The solvent was removed to yield a yellow oil (29.20 g, including residual solvent) which was used directly in Step B. ~H-NMR; 8 (CDC13), 7.34 - 7.19 (5H, m), 4.73 - 4.63 (1 H, m), 4.25 - 4.16 (2H, m), 3.30 (1 H, dd, J = 3.3 Hz), 3.05 - 2.85 (2H, m), 2.78 (1 H, dd, J = 9.5 Hz), 1.76 - 1.53 (3H, m) and 0.9T (6H, d, J = 6.2 Hz).
TEP B:
N-(4-(tert-Butyl)-2R-isobutyl-but.an-1,4-dioyl)-4S-phenylmethyl-oxazolidin-2-one N-(4-Methylpentanoyl)-4S-phenylmethyl-oxazolidin-2-one (20 g, 72.6 mmol) was placed in a dry 1 litre 3-necked flask to which was added dry THF (400 ml).
The mixture was kept under a stream of argon and cooled to -78°C (dry ice/acetone).
Sodium bis(trimethyl)silylamide (1 M solution in THF, 72.6 ml, 72.6 mmol) was added dropwise through a dropping funnel. After stirring for 20 minutes, terf butyl bromoacetate (21.02 g, ~I5.8 ml, 109 mmol) was added dropwise over 1 minute, to give an orange solution. The mixture was kept at -78°C and allowed to warm to -50°C over 2 hours (after' which time it turned pink). The reaction was then quenched by adding acetic acid (10.90 g, 10.4 ml, 182 mmol) in ether (50 ml) at -50°C, whereupon the solution became colourless. The solvent was removed PC'TIGB95/00111 under reduced pressure and the resulting slurry was partitioned between ethyl acetate and brine. The ethyl acetate layer was washed once with brine and the original brine layer was back-extracted with ethyl acetate. The combined organic layers were dried and the solvent removed, giving a yellow oil which crystallised on cooling overnight to yield the title compound as a crystalline solid (21.36 g, 76%).
~H-NMR; 8 (CDC13), 7.38 - 7.24 (5H, m), 4.67 (1 H, m), 4.27 (1 H, m), 4.18 -4.16 (2H, m), 3.36 (1 H, dd, J = 3.3 Hz), 2.72 (1 H, dd, J = 2.3 Hz), 2.49 (1 H, dd, J =
4.6 Hz), 1.72 - 1.24 (3H, m), 1.44 (9H, s) .and 0.91 - 0.96 (6H, dd, J = 4.5 Hz).
[a]25p = + 66.9°
(c=1, MeOH).
TEP
2R-Isobutyl-butan-1,4-dioic acid-~4-ten-butyl ester N-(4-(tent Butyl)-2R-isobutyl-but;an-1,4-dioyl)-4S-phenylmethyl-oxazolidin-2-one (15.30 g, 39 mmol) was placed in a 1 litre flask with a stirrer bar and to it was added a mixture of THF (600 ml) and water (150 ml). The solution was stirred and cooled to 0°C (ice/acetone bath) then 60% aq. hydrogen peroxide (4.5 ml, 157 mmol) was added via syringe over 5 minutes, followed by lithium hydroxide (2.65 g, 63 mmol) in 100 ml water. The reaction mixture was stirred for 1 h at 0 °C. TLC
analysis (10% methanol in dichloromethane) showed complete reaction (product gave a yellow spot on TLC on staining vvith bromocresol green and heating). The reaction mixture was quenched with sodium nitrite (10.88 g, 157 mmol), the final pH was 13. THF was removed in-vacuo and the aqueous layer was extracted with dichloromethane (3 x 200 ml) to recover the chiral auxiliary. The organic extracts were dried (anhydrous magnesium sulphate), filtered and the solvent removed in-vacuo and the resulting :>olid chiral auxiliary (7.05 g, 39 mmol, 100%) recrystallised from ethyl acetate-hexane (2:1 ). [a]25p = - 13.0° (c=1, MeOH) The aqueous layer was cooled in an ice bath and acidified to pH 5-6 with 2M
hydrochloric acid. The rE~sulting cloudy solution was extracted with ethyl acetate (4 WO 95!19956 Z ~ g . PCTlGB95/00111 x 200 ml), readjusting the pH to 5-6 in between extractions. The combined organic extracts were dried over rnagnesiium sulphate, filtered and the solvent was removed to yield the title compound as a pale yellow oil (8.21 g, 91%). ~H-NMR; b (CDC13), 2.85 (1 H, m), 2.59 (1 H, dd, J = 16, 9 Hz), 2.38 (1 H, dd, J = 16, 5 Hz), 1.64 (1 H, m), 1.43 (9H, s), 1.28 (1 H, m) and 0.93 (6H, dd, J = 7, 8 Hz). [a)25o =
+ 10.4°
(c=1, MeOH) T P
Na-Benzyloxycarbonyl-L-phenylalanine-N-phenylamide Na-Benzyloxycarbonyl-L-phenylalanine (4.95 g, 16.5 mmol) was dissolved in dichloromethane (70 ml) and the solution was cooled to 0°C and stirred during the addition of pentafluorophenol (3.35 g, 18.2 mmol), followed by EDC (3.49 g, 18.2 mmol). The mixture was allowed to warm to room temperature, stirred for a further 1 hour then cooled back to 0°C. ,Aniline (3.85 g, 41.4 mmol) was added dropwise and the mixture was warrn~ed to room temperature then stirred overnight. The solution was washed twicE~ with 1.M sodium carbonate, twice with 1 M
hydrochloric acid and finally with brine before drying over anhydrous magnesium sulphate.
The solution was filtered and evaporated to a white solid which was recrystallised from ethyl acetate-hexane. Yielld: 2.57 g (41 %). ~ H-NMR; b (CDC13), 7.87 (1 H, br s), 7.43 - 7.03 (15 H, br m), 5.62 (1 H, m), 5.08 (2H, s), 4.59 (1 H, s) and 3.15 (2H, s).
T P
L-Phenylalanine-N-phenylamide Na-Benzyloxycarbonyl-L-phenylalanine-N-phenylamide (2.50 g, 6.68 mmol) was dissolved in ethanol (20 ml) and cyclohexene (5 ml) and 10% palladium on charcoal (250 mg) was added. The mixture was heated at reflux for 1 hour after which time no starting material was detectable (as indicated by TLC analysis).
The catalyst was removed by filtration and the solvent evaporated to leave the title compound contaminated with reaidual ethanol (1.74 g). ~H-NMR; 8 (CD30D), 7.45 (2H, m), 7.18 (7H, m), 7.I)4 (1 H, m), 3.56 (1 H, m), 3.04 (1 H, dd, J = 6.4, 13.3 Hz) and 2.85 (1 H, dd, J = 7.2, 13.3 Hz).
STEP F:
5-Methyl-3R-(2-phenyl-1 S-phenylcarbamoyl-ethylcarbamoyl)-hexanoic acid tert butyl ester 2R-Isobutyl-butan-1,4-dioic acid-4-tert-butyl ester (1.17 g, 5.11 mmol), prepared according to the method describE~d in STEP C, was dissolved in DMF (30 ml) and the solution was cooled in an ice bath. HOBt (0.76 g, 5.62 mmol) and EDC (1.07 g, 5.62 mmol) were added and the reaction mixture was stirred for 90 minutes at 0°C
and 30 minutes at room temperai:ure. The mixture was cooled back to 0°C, L-phenylalanine-N-phenylamide (1 .60 g, 6.65 mmol) was added and the reaction mixture was allowed to warm to room temperature with stirring overnight. TLC
analysis indicated that all of the carboxylic acid precursor had been consumed.
The solvent was removed and the residue was taken up in diethyl ether and washed successively with water, 1 M sodium carbonate, 1 M hydrochloric acid and brine. The organic phasE~ was dried (anhydrous magnesium sulphate), filtered and evaporated to leave an o1ff-white solid. Recrystallisation from ethyl acetate-hexane afforded the title compound (1.23 g, 53%). ~ H-NMR; b (CDC13), 8.16 (1 H, s), 7.39 (2H, m), 7.28 (7H, m), 7.08 (1 H, m), 6.53 (1 H, d, J = 7.7 Hz), 4.82 (1 H, dd, J = 7.2, 14.5 Hz), 3.22 (2H, m), 2.66 (1 H, m), 2.52 (1 H, dd, J = 8.6, 16.4 Hz), 2.37 (1 H, dd, J
= 4.9, 16.4 Hz), 1.45 (2H, m), 1.43 (9H, s), 1.20 (1 H, m), 0.86 (3H, d. J =
6.4 Hz) and 0.81 (3H, d, J = 6.2 Hz).
T P
5-Methyl-3R-(2-phenyl-1 ~>-phenylcarbamoyl-ethylcarbamoyl)-hexanoic acid WO 95/19956 ~ ~ ~ PCT/GB95/00111 5-Methyl-3R-(2-phenyl-1 S-phenylcarbamoyl-ethylcarbamoyl)-hexanoic acid terf butyl ester (1.22 g, 2.70 mmol) was dissolved in dichloromethane (7.5 ml) and TFA
(7.5 ml) and the solution was stored overnight at 4°C. The solvents were removed in vacuo, the residue was dissohved in ethyl acetate and washed twice with water to remove residual TFA. The organic phase was dried (anhydrous magnesium sulphate), filtered and evaporated to leave a foam (1.07 g, including residual solvent). ~ H-NMR; b (CD~3 OD), i'.41 (2H, m), 7.18 (7H, m), 7.02 (1 H, m), 4.70 (1 H, dd, J = 7.0, 8.1 Hz), 3.17 (1 H, dd, J = 7.0, 13.7 Hz), 3.03 (1 H, dd, J =
8.1, 13.7 Hz), 2.76 (1 H, m), 2.44 (1 H, dd, J = 8.4, 16.5 Hz), 2.28 (1 H, dd, J = 5.9, 16.5 Hz), 1.40 (2H, m), 1.21 (1 H, m), 0.83 (3H, d, J = 6.3 Hz) and 0.76 (3H, d, J = 6.2 Hz).
TS EP H:
O-Benzyl-5-Methyl-3R-(~?-phenyl-1 S-phenylcarbamoyl-ethylcarbamoyl)-hexanohydroxamate 5-Methyl-3R-(2-phenyl-1 S-phenylcarbamoyl-ethylcarbamoyl)-hexanoic acid (1.00 g, 2.52 mmol) was dissolved in DMF (5 ml) and cooled to 0°C in an ice bath. HOBt (0.41 g, 3.03 mmol), EDC (0.58 c~, 3.03 mmol) and NMM were added and the mixture was stirred for 1 hour at 0°C followed by a further 2 hours at room temperature. The reaction was cooled back to 0°C during the addition of O-benzylhydroxylamine (0.47 g, 3.78 mmol) and then allowed to warm to room temperature with stirring overnight. The solvent was removed in vacuoto leave an oil which crystallised on stirring with diethyl ether and water. Trituration with ethyl acetate gave the required product (0.63 g, 50%) which was used in STEP I
without further purification. ~H-NMR; 8 (CD3OD), 7.45 (2H, m), 7.38 -7.08 (12H, m), 7.04 (1 H, m), 4.76 (2H, m), 4.E~9 (1 H, rn), 3.19 (1-H, dd, J = 6.7, 13.8 Hz), 3.00 (1 H, dd, J =
8.6, 13.8 Hz), 2.75 (1 H, m), 2.16 (1 H, dd, J = 8.0, 14.5 Hz), 2.02 (1 H, dd, J = 6.7, 14.5 Hz), 1.38 (2H, m), 1.18 (1 H, m), 0.81 (3H, d, J = 6.3 Hz) and 0.75 (3H, d, J =
6.2 Hz).
T PI:

5-Methyl-3R-(2-phenyl-1 S-phenylcarbamoyl-ethylcarbamoyl)-hexanohydroxamic acid Hydrogen gas was bubbled through a-slurry of O-benzyl-5-Methyl-3R-(2-phenyl-1 S-phenylcarbamoyl-ethylcarbamoyl)-hexanohydroxamate (0.62 g, 1.23 mmol) and 10% palladium on charcoal (0.12 g) in ethanol (30 mi) for 90 minutes, after which time no starting material remained (as indicated by TLC analysis). The catalyst was removed by filtration and the filtrate was evaporated to leave a white solid. Recrystallisation from ethanol-ethyl acetate afforded the title compound (0.37 g, 73%). m.p. 183 - 184~'C. ~H-NMR: 8 (CD3 OD), 7.45 (2H, m), 7.20 (7H, m), 7.05 (1 H, m), 4.70 (1 H, dd, J = 7.0, 8.2 Hz), 3.17 (1 H, dd, J = 7Ø 13.7 Hz), 2.99 (1 H, dd, J = 8.3. 13.7 Hz), 2.76 (1 H, rn), 2.16 (1 H, dd. J = 7.4, 14.5 Hz), 2.04 (1 H, dd, J
= 7.2, 14.5 Hz), 1.41 (2H, m). 1.08 (1 H. m), 0.83 (3H, d, J = 6.4 Hz) and 0.77 (3H, d, J = 6.4 Hz). ~3C-NMR; 8 (CD3 OD), 177.3, 171.7, 170.6, 139.3, 138.5, 130.9, 129.7, 129.5, 127.7, 12:1.5, 121.8, 56.8, 42.5, 42.4, 39.0, 36.9, 26.9, 23.4 and 22.4.
Found: C 65.64, H 6.96, N 9.91 °ro; C2oH3~ N3O5 . 0.5 H20 requires: C
65.70, H 7.19, N 9.99%.
The following additional compounds were prepared according to the methods of Example 1:

3R-(2,2-Dimethyl-1 S-phenylcarbamoyl-propylcarbamoyl)-5-methyl-hexanohydroxamic acid H '~'~ H H
N N \
H
O /
CONHOH

WO 95/19956 ~ ~ . PCTIGB95/00111 White powder. m.p. 151 - 153°C. ~ H-NMR: 8 (CD30D), 7.48 (2H, d, J =
7.8 Hz), 7.26 (2H, t, J = 7.6 Hz), 7.05 {1 H, t, J = 7.3 Hz), 4.40 (1 H, s), 2.95 {1 H, m), 2.31 {1 H, dd, J = 7.8, 14.6 Hz), 2.15 (1 H, dd, J = 6.6, 14.6 Hz), 1.51 (2H, m), 1.20 (1 H, m), 1.03 (9H, s), 0.86 (3H, d, J = 6.4 Hz) and 0.81 (3H, d, J = 6.3 Hz). ~3C-NMR; 8 (CD30D), 177.2, 171.2, 170.6, 139.3, 129.8, 125.5, 121.6, 62.7, 42.5, 41.9, 37.1, 35.8, 27.2, 27.0, 23.5 and 22.6. Found: C 62.86, H 8.29, N 10.71 %; C2oH3i N304 .
0.3 H20 requires: C 62.74, H 8.:12, N 10.97%

3R-(2.2-Dimethyl-1 S-pyridin-2-ylcarbamoyl-propylcarbamoyl)-5-methyl-hexanohydroxamic acid O
H .~~~ H N N
H /
O
CONHOH
Pale grey solid. m.p. 125 - 126°C. ~ H-NMR; 8 (CD30D), 8.26 (1 H, m), 8.04 (1 H, d), 7.72 (1 H, dt, J = 1.9, 5.5 Hz), 7.07 (1 H, m), 4.47 (1 H, s), 2.97 (1 H, m), 2.30 (1 H, dd, J = 7.8, 14.5 Hz), 2.'18 (1 H, dd, J = 6.6, 14.5 Hz), 1.51 (2H, m), 1.15 (1 H, m), 1.03 (9H, s), 0.86 (3H, cl, J = 6.5 Hz), and 0.80 (3H, d, J = 6.4 Hz). ~3C-NMR; 8 (CD30D), 177.3, 171.6, 170.6, '152.6, 149.1, 139.5, 121.1, 115.7, 62.8, 42.5, 41.9, 37.0, 35.7, 27.2, 27.0, 23.5 and 22.5. Found: C 60.11, H 7.90, N 14.79%;
Ci9H3oN404 requires: C 60.30, I~ 7.99, N 14.80%.

3R-(2,2-Dimethyl-1 S-phenylcarbamoyl-propylcarbamoyl)-2S-hydroxy-5-methylhexanohydroxamic acid O
H ~H H
N .,~ N
H I
HO~ ' CONHOH O
H
TEP A:
2S-Hydroxy-3R-isobutenyl-butan-1,4-dioic acid diisopropyl ester 2S-Hydroxybutan-1,4-dioic acid diisopropyl ester (50 g, 230 mmol) was added to a solution of LDA [from N,N-diisopropylamine (80 ml, 570 mmol) and 10 M n-butyllithium (48.1 ml, 481 mmol)] in dry THF (500 ml) whilst maintaining the temperature at -70°C. When addition was complete the reaction was warmed to 15°C and stirred for 8 hours. ThE~ reaction mixture was cooled to -70°C and methallyl iodide (46 g, 252 mmol) was added slowly, ensuring that the temperature did not exceed -65°C. Ths~ mixture was warmed to -40°C and stirred for 18 hours before quenching at -15°C with citric acid. The organic layer was separated and washed with 10% sodium hydrogen carbonate solution (500 ml) and brine (300 ml) then dried (anhydrous magnesiurn sulphate). The solution was filtered and concentrated in vacuo to give a brown oil (64 g) which was purified by column chromatography (silica gel, 1 kg, gradient elution with 20 to 35% diethyl ether in hexane). The desired product was isolated as a colourless oil (30.9 g, 49%) which was found to be a 17:1 mixture of diastereoisomers by NMR. ~ H-NMR; b (CDC13, major diastereoisomer), 5.06 (1 H, septet, J = 6.3 Hz), 4.97 (1 H, septet, J =
6.3 Hz), 4.78 (2H, d, J = 7.1 Hz), 4.16 (1 H, m), 3.20 (1 H, d, J = 6.2 Hz), 3.00 {1 H, m), 2.50 (1 H, dd, J = 7.0, 14.5 Hz), 2.35 (1 I~, dd, J = 8.7, 14.4 Hz), 1.72 (3H, s) and 1.24 -1.16 (12H, 2m).
STEP B
2S-Hydroxy-3R-isobutyl-butan-t ,4-dioic acid diisopropyl ester WO 95/19956 ~ PCT~GB95/00111 --2S-Hydroxy-3R-isobutenyl-butan-1,4-dioic acid diisopropyl ester (7.14 g, 26.2 mmol) was dissolved in ethanol (80 ml), and stirred overnight with 10%
palladium on charcoal catalyst (1.0 g) under an atmosphere of hydrogen. The catalyst was removed by filtration and the filtrate was evaporated to dryness to leave the product as a clear oil (7.03 g, 98°/<>). ~H-NMR; 8 (CDC13), 5.06 (1 H, septet, J = 6.3 Hz), 4.97 (1 H, septet, J = 6.3 Hz), 4.17 (1 H, br s,), 3.24 (1 H, br s), 2.83 (1 H, m), 1.68 (2H, m), 1.44 (1 H, m), 1.24 (6H, d, J = 6.2 Hz), 1.t8 (6H, d, J = 6.2 Hz) and 0.89 (6H, m).
T P
2S-Hydroxy-3R-isobutyl-butan-1,4-dioic acid 2S-Hydroxy-3R-isobutyl-butan-1,4-dioic acid diisopropyl ester (7.0 g, 25.6 mmol) was dissolved in dioxane (15 ml) and water (15 ml), a solution of potassium hydroxide (4.29 g) in water (22 ml) was added and the mixture was heated at 90°C
overnight. The solution was allovved to cool and then passed through an ion exchange resin (Dowex 50X4-400, 200 ml) and evaporated to yield the title compound (4.82 g, 99%). ~H-NMR; 8 (CDC13), 8.70 (2H, br s), 4.32 (1 H, br s), 3.10 (1 H, m), 1.85 - 1.55 (3H, m) and 1).96 (6H, m).
T P
2R-(2,2-Dimethyl-4-oxo-1,3-dioxalan-5S-yl)-4-methylpentanoic acid 2S-Hydroxy-3R-isobutyl-butan-1,4-dioic acid (5.19 g, 27.3 mmol) was dissolved in 2,2-dimethoxypropane (150 ml) and DMF (40 ml) and stirred overnight at 30°C in the presence of a catalytic amount of p-toluene sulphonic acid. The solvent was removed to give the title compound contaminated with solvent (6.87 g, crude).
~H-NMR; 8 (CDC13), 4.41 (1 H, d, J = 4.8 Hz), 2.91 (1 H, m), 1.69 (3H, m), 1.54 (3H, s), 1.48 (3H, s) and 0.88 (6H, m).

PCTlGB95/00111 TEP
2R-(2,2-Dimethyl-4-oxo-1,3-diox:alan-5S-yl)-4-methyl pentanoic acid pentafluorophenyl ester -2R-(2,2-Dimethyl-4-oxo-'1,3-dioxalan-5S-yl)-4-methylpentanoic acid (558 mg, 2.4 mmol) was taken up in dichloronnethane (10 ml) and cooled to 0°C before adding pentafluorophenol (670 mg, 3.6 mmol) and EDC (560 mg, 2.9 mmol). The reaction was stirred at 0°C for 2 hours thE~n the solution was washed with 1 M
sodium carbonate (50 ml) and brine (20 ml). The organic layer was dried (magnesium sulphate), filtered, evaporated to dryness and purified by column chromatography (silica gel, dichloromethane} to dive the activated ester (552 mg, 58%). ~ H-NMR; 8 (CDC13), 4.57 (1 H, d, J = ~5.5 Hz), 3.32 (1 H, m), 1.86 (3H, m), 1.67 (3H, s), 1.58 (3H, s) and 1.03 (6H, m).
T P F:
L-tert-leucine-N-phenylarnide The title compound was prepared from N-benzyloxycarbonyl-L-teri-leucine by methods analogous to those described in Example 1 (STEPS D and E). ~ H-NMR;
8 (CDC13), 7.53 (2H, m), 7.28 (2H, m), 7.06 (1 H, m), 3.13 (1 H, s) and 1.00 (9H, s).
T P
N2-[2R-(2,2-Dimethyl-4-o:KO-1,3-clioxalan-5S-yl)-4-methylpentanoyl)-L-terf leucine-N-phenylamide 2R-(2,2-Dimethyl-4-oxo-1,3-dioxalan-5S-yl)-4-methylpentanoic acid pentafluorophenyl ester (1.72 g, 5.77 mmol) and L-tert leucine-N-phenylamide (1.25 g, 6.06 mmol) were dissolved in DMF (150 ml) and the mixture was stirred WO 95/19956 ~ 1 . ~ PCTlGB95/00111 ---overnight at room temperature. The solvent was removed to give an oil which dissolved in diethyl ether and the solution was washed twice with 1 M sodium carbonate and then with brine. 'The organic phase was dried (anhydrous magnesium sulphate), filtered and evaporated to an oil. Crystallisation from ethyl acetate-hexane afforded the desired product as a white solid (1.55 g, 64%). ~H-NMR; 8 (CDC13), 8.53 (1 H, s), 7.49 (2H, m), 7.26 {2H, m), 7.09 (1 H, m), 7.00 (1 H, d), 4.58 (1 H, d), 4.52 {1 H, d), 2.84 ('I H, m), 1.78 - 1.47 (3H, br m), 1.64 (3H, s), 1.54 (3H, s), 1.09 (9H, s), 0.88 (.3H, d, J = 5.9 Hz) and 0.83 (3H, d, J = 6.0 Hz).
STEP H:
3R-(2,2-Dimethyl-1 S-phenyicarbamoyl-propylcarbamoyl)-2S-hydroxy-5-methyl-1-hexanohydroxamic acid To a solution of hydroxylamine hydrochloride (0.93 g, 13.36 mmol) in methanol (10 ml) was added sodium methoxide (0.72 g, 13.36 mmol) and the mixture was stirred at room temperature for .2 hours, after which time the precipitated solid was removed by filtration. The filtrate was cooled in an ice bath prior to the addition of N2-[2R-(2,2-dimethyl-4-oxo-1,3-~dioxalan-5S-yl)-4-methylpentanoyl)-L-tert leucine-N-phenylamide (1.40 g, 3.34 mmol) which was added in portions. The mixture was stirred at 0°C for 10 minutes then allowed to warm to room temperature and stirred overnight. The solvent v~ras removed under reduced pressure and the residue was purified by column chromatography {acid washed silica, 5% methanol in dichloromethane) followE~d by crystallisation from ethyl acetate-hexane.
Yield: 0.89 g (68%). m.p. 122 - 124°C. ~ H-NMR; 8 (CD30D), 7.51 (2H, d, J = 7.8 Hz), 7.27 (2H, m), 7.06 (1 H, m), 4.40 (1 H, s), 4.02 (1 H, d, J = 6.1 Hz), 2.86 (1 H, m), 1.64 (1 H, m), 1.51 (1 H, m), 1.26 (1 H, m), 1.03-(9H, s), 0.89 (3H, d, J = 6.4 Hz), and 0.84 (3H, d, J = 6.4 Hz). ~3C-NMR; 8 {(CD3)ZSO), 172.6, 169.2, 168.8, 138.7, 128.6, 123.3, 119.3, 71.4., 60.5, 47.7, 37.3, 34.5. 26.6, 25.3, 23.5 and 21.8.
Found:
C 60.08, H 7.97, N 10.44% ; C2oH3~ N305 . 0.4 H20 requires: C 59.95, H 8.00, N
10.49%.

The following additional compounds were prepared according to the methods of Example 4:

2S-Hydroxy-3R-(3-methyl-1 S-napth-2-ylcarbamoyl-butylcarbamoyl)-5-methyl-hexanohydroxamic acid H _~~~ H
~~ N NH
H I
HO- ' CONHOH O
H
Off-white crystalline solid. m.p. 186°C. ~H-NMR; b (CD30D), 8.24 (0.5H, d, J = 7.8 Hz), 8.15 (1 H, s), 7.80 - 7.64 (3h1, m), 7.54 (1 H, br d, J = 7.4 Hz), 7.43 -7.29 (2H, m), 4.70 - 4.50 (1 H, m), 4.03 (1 HI, d, J = 6.8 Hz), 2.90 - 2.74 (1 H, m), 1.83 - 1.41 (5H, m), 1.27 - 1.10 (1 H, m), 0.9!5 (3H, d, J = 5.2 Hz), 0.93 (3H, d, J = 5.4 Hz), 0.89 (3H, d, J = 6.4 Hz), and 0.82 (3H, d, J = 6.4 Hz). ~3C-NMR; 8 (CD30D), 176.0, 173.3, 171.5, 161.7, 136.9, 135.1, 132.1, 129.5, 128.5, 127.4, 126.0, 121.4, 118.2, 73.1, 54.1, 54.0, 41.8, 39..1, 26.9, 25.8, 23.8, 23.6, 22.2 and 22Ø I R; vm~
(KBr), 3422, 2917, 2850, 2363 and 1636.

21~~~~7t~

2S-Hydroxy-3R-(3-methyl-1 S-(4-methoxyphenyl)carbamoyl-butylcarbamoyf)-5-methyl-hexanohydroxamic acid O
,,A H NH
N
. " o ~ I
HO - CONHOH OMe H
White powder. m.p. 192°C. ~H-NMR: b (CD30D), 7.33 (2H, d, J = 8.8 Hz), 7.30 -7.10 (5H, m), 6.80 (2H, d, J = 8.E! Hz), 4.67 (1 H, br dd 7.4, J = 7.3 Hz), 4.01 (1 H, d, J = 5.9 Hz), 3.72 (3H, s)., 3.19 (1 H, dd. J = 6.3, 13.6 Hz), 3.02 (1 H, dd, J
= 8.1, 13.9 Hz), 2.79 - 2.60 (1 H, m), 1.58 - 'I .40 (1 H, m), 1.40 - 1.19 (1 H, m), 1.20 -1.06 (1 H, m), 0.80 (3H, d, J = 6.5 i-Iz) and 0.77 (3H, d, J = 6.6 Hz). ~3C-NMR; 8 (CD30D), 175.6, 171.5, 158.2, 138..4, 132.1, 130.4, 129.5, 127.8, 123.6, 114.8, 72.9, 56.7, 55.8, 39.2, 39.0, 26.7, 2~~.8 and ;?2.1. IR; vm~ (KBr), 3420, 2343, 1653 and cm-~ .

3R-(2,2-Dimethyl-1 S-(4-tnrtbutyl~~2,6-dimethylphenyl)carbamoyl-propylcarbamoyl)-2S-hydroxy-5-methylhexanohydnoxamic acid O Me H ~ 'H H
N .,~ N
H I
O
HO~~ CONHOH Me ~ tBu H

White solid. m.p. 209 - 210°C. ~ I-i-NMR; b (CD30D), 7.07 (2H, s), 4.53 (1 H, s), 3.98 (1 H, d, J = 7.2Hz), ;?.87 (1 HI, m), 2.16 (6H, s), 1.64 (1 H, m), 1.51 (1 H, m), 1.25 (9H, s), 1.16 (1 H, m), 1.10 (9H, s), and 0.87 (6H, m). ~3C-NMR; 8 (CD30D), 175.5, 171.8, 171.7, 151.4, 136.2, 132.7, 126.2, 73.3, 62.1, 39.4, 35.6, 35.1, 31.7, 27.4, 26.9, 24.0, 22.2 and 19.3. Found: C 64.23, H 8.91, N 8.69% ; C26H~N305 .
0.5 H20 requires: C 64.17, H 9.11, N 8.63%.
3R-(2,2-Dimethyl-1 S-pyridin-2-ylcarbamoyl-propylcarbamoyl)-2S-hydroxy-5-methylhexanohydroxamic acid O
H ,,,.v H N N
H ( \
HO~ - CONHOH O
H
White powder. m.p. 132..5 - 134.5 °C. ~ H NMR; 8 (CDC13), 9.97 (1 H, s), 9.52 (1 H, s), 8.73 (1 H, d, J =11.0 f-Iz), 8.18 (2H, m), 7.81 (1 H, m), 7.13 (1 H, m), 4.78 (1 H, d, J =10.9 Hz), 4.19 (1 H, m), 2.95 ('I H, m), 2.00 (1 H, m), 1.53 (1 H, m), 1.42 (1 H, m), 1.10 (9H, s), 0.86 (3H, d, J = 6.2 Hz) and 0.85 (3H, d, J = 6.1 Hz). ~3C NMR;

(CDC13), 174.4, 170.1, 1 fi9.0, 152.0, 146.3, 139.9, 120.1, 116.2, 73.8, 63.2, 42.0, 39.8, 34.8, 27.0, 25.8, 23.0 and 21.8. Found: C 57.33, H 7.53, N 13.84% ;
C26H~N305 . 0.2 H20 requires: C 57.33, H 7.70, N 14.07%.

WO 95/19956 ~ ~ . PCTIGB95/00111 ...

3R-(2,2-Dimethyl-1 S-(4-methoxyphenyl)carbamoyl-propylcarbamoyt)-2S-hydroxy-5-methylhexanohydroxarnic acid O
H ~ .,av H N
H
HO 'CONHOH O ~ OMe H
Pale brown solid. m.p. 118-120°C. ~H NMR; 8 (CD30D), 7.39 (2H, d, J =
9.4 Hz), 6.81 (2H, d. J = 9.4 Hz), 4.37 (1 H, s), 4.15 (1 H. d, J = 6.9 Hz), 3.73 (3H, s), 2.91 -2.79 (1 H, m), 1.70 - 1.44 (2H, m), 1.33 - 1.13 (1 H, m), 1.03 (9H, s), 0.89 (3H, d, J =
6.3 Hz), and 0.85 (3H, d, J = 6.3 Hz). ~3C NMR; 8 (CD30D), 175.6, 171.5, 171.0, 158.2, 132.1, 123.6, 115.0, 73.1, 62.4, 55.9, 39.7, 35.9, 30.9, 27.2, 27.0, 23.6 and 22.4. IR, vmax (KBr) 341!3, 2923, 2361, 1654, 1512, 1458, 1245, 1036 cm-~.
Found:
C 57.97%, H 7.73%, N 9.31 %; C~2~ H3gNgOg . 0.6 H20 requires C 58.08%, H
7.94%, N 9.67%.

3R-(2,2-Dimethyl-1 S-pyridin-4-ylcarbamoyl-propylcarbamoyl)-2S-hydroxy-5-methylhexanohydroxamic acid O
H , ~~ H H
N , N
H O ~ iN
HO CO_NHOH
H
White solid. m.p 120 - 1 c'S°C. ~ H-NMR; 8 ((CD3)2S0, 9:1 mixture of diastereoisomers), 10.62 (1 H, s), 10.59 (0.9H, s), 10.43 (0.1 H, s), 8.40 (2H, d, J =
6.2 Hz), 7.80 (0.9H, d, J =: 8.6 Hz}, 7.76 (0.1 H, d, J = 6.3 Hz), 7.60 (2H, d, J = 6.2 Hz), 5.60 (0.1 H, s), 5.29 (0.9H, s), 4.44 (0.9H, d, J = 8.7 Hz), 4.31 (0.1 H, d, J = 8.5 Hz), 3.72 (1 H, br d), 2.90 (1 H, m),. 1.49 (3H, m), 1.04 (9H, s) and 0.81 (6H, m).
~3C-NMR; 8 ((CD3)2S0, !a:1 mixture of diastereomers), 173.5, 172.9, 170.7, 170.6, 168.7, 150.1, 150.0, 145..3, 145.:3, 113.5, 113.2, 71.2, 61.0, 60.8, 47.5, 46.6, 37.2, 36.1, 34.3, 34.1, 26.6, 26.4, 25.2, 23.8, 23.4, 21.7 and 21.4.

3R-(2,2-Dimethyl-1 S-pyridin-3-ylcarbamoyl-propylcarbamoyl)-2S-hydroxy-5-methylhexanohydroxamic; acid O
''~~ H N
~N
i: O ~ /
HO CONHOH
I~
White solid. m.p 108-112°C. ~ H-IVMR; 8 ((CD3)2S0), 10.60 (1 H, s), 10.26 (1 H, s), 8.90 (1 H, s), 8.74 (1 H, s), 8.26 (1 H, d, J = 4.4 Hz), 8.05 (1 H, d, J = 8.2 Hz), 7.77 (1 H, d, J = 8.7 Hz), 7.36 (1 H, m), 5.32 (1 H, d, J = 8.2 Hz), 4.45 (1 H, d, J = 8.9 Hz), 3.75 (1 H, m), 2.81 (1 H, m), 1.40 (3H, m), 0.98 (9H, s) and 0.80 (6H, dd, J =
12.5, 6.2 Hz). ~3C-NMR; 8 (CD;3)2S0, '172.7, 169.8, 168.7, 144.2, 140.9, 135.3, 126.2, WO 95119956 ~ ~ PCT/GB95/00111 123.5, 71.2, 60.5, 47.6, 3'7.3, 34.3, 26.5, 25.3, 23.4 and 21.7. Found: C
54.46, H
7.46, N 13.42%; C~9H3oN40$ . 1.2 H20 requires C 54.85, H 7.85, N 13.46%.

3R-(2,2-Dimethyl-1 S-(4-hydroxyphenyl)carbamoyl-propylcarbamoyf)-2S-hydroxy-5-methylhexanohydroxamic acid O
H ~ ,~~~~ H H
N N
H I
HO _ ~CONHOH O ~ QH
H
White solid. m.p. 138-147°C. ~ H-NMR; 8 ((CD3)2S0), 10.59 (1 H, s), 9.71 (1 H, s), 9.17 (1 H, s), 8.88 (1 H, s).. 7.61 (1 H, d, J = 9.2 Hz), 7.36 (2H, d, J = 8.7 Hz), 6.69 (2H, d, J = 8.7 Hz), 5.29 (1 H, d, J = 8.7 Hz), 4.40 (1 H, d, J = 9.2 Hz), 2.80 (1 H, m), 1.49 (2H, m), 1.29 (1 H, m), 0.95 (9H, s) and 0.80 (3H, d, J = 6.4 Hz) and 0.75 (3H, d, J = 6.4 Hz). ~3C-NMR; 8 ((CD,3)2S0), 172.4, 168.7, 168.4, 153.3, 130.3, 121.1, 114.9, 71.3, 60.3, 47.7, 37.2, 34.7, 26.6, 25.3, 23.4 and 21.7. Found: C
57.28%, H
7.67%, N 10.17%; C2oH3~ N306 . ().5 H20 requires C 57.40%, H 7.71 %, N 10.04%.

3R-(2,2-Dimethyl-1 S-(3-methoxyphenyl)carbamoyl-propylcarbamoyl)-2S-hydroxy-5-methylhexanohydroxamic acid O
H ~ _~~~ H H
N N ~ OMe H I
HO CONHOH O
H
White solid. m.p. 97 - 102°C. ~ H-NMR; 8 ((CD3)2S0), 10.58 (1 H, s), 9.96 (1 H, s), 8.87 (1 H, s), 7.67 (1 H, d, J = 9.2 Hz), 7.29 (1 H, s), 7.20 (2H, m), 6.64 (1 H, d, J = 7.8 Hz), 5.29 (1 H, d, J = 7.9 Hz), 4.43 (1 H, d, J = 9 Hz), 3.72 (3H, s), 2.77 (1 H, m}, 1.50 (3H, m), 0.97 (9H, s), 0.81 (3H, d, J = 6.4 Hz) and 0.78 (3H, d, J = 6.4 Hz).
~3C-NMR; b ((CD3)ZSO), 172.6, 169.3, 168.7, 159.4, 139.8, 129.4, 111.6, 108.6, 105.2, 71.3, 60.5, 54.9. 47.6, 37.3. 34.4, 26.5. 25.3. 23.4 and 21.8. Found: C
57.96%, H 7.58% N 9.39%; C2~ H33N3~6 . 0.7 H20 requires C 57.84%, H 7.95%, N
9.63%.

3R-(2-Benzylthio-2-methyl-1 S-(pyridin-2-ylcarbamoyl)propylcarbamoyl)-2S-hydroxy-5-methylhexanohydroxa~mic acid /I
S
O
H ,,,~~ H N N
H_ I w HO~- CONHOHO /
H
White foam. m.p. 112 - 115°C. ~ H-NMR; 8 (CD30D), 8.26 (1 H, m), 8.06 (1 H, d, J =
8.4 Hz), 7.73 (1 H, m), 7.'I 1-7.29 (5H, m), 7.07 (1 H, m), 4.68 (1 H, s), 4.15 (1 H, d, J =

WO 95/19956 2 ~ g 1 =) ~ ~ PCTIGB95100111 4.7 Hz), 3.80 (2H, m), 2.93 (1 H, m), 1.55-1.71 (1 H, m), 1.48 (3H, s), 1.44 (3H, s), 1.47-1.23 (2H, br m), 0.90 (3H, d, J = 6.4 Hz) and 0.84 (3H, d, J = 6.3 Hz).
~3C-NMR; 8 (CD30D), 1'75.7, 171.7, 170.5, 152.3, 149.0, 139.8, 138.8, 130.3, 129.4, 128.0, 121.4, 115.9, 73.0, 61.4, 49.5, 49.3, 39.8, 34.2, 32.8, 26.9, 26.9, 26.2, 23.6 and 22.4. Found: C 59.78%, H 6.97%, N 10.86%; C25H34N4O5S
requires C 59.74%, H 6.E32% N 11.15%

3R-(2,2-Dimethyl-1 S-(thiazol-2-ylcarbamoyl)-propylcarbamoyl)-2S-hydroxy-5-methylhexanohydroxamic acid O
H .,~~~ H H
N~S
. _: O N
HO CONHOH
H
White solid. m.p. 125-128°C. ~ H-NMR; 8 ((CD3)2S0), 10.60 (1 H, s}, 8.86 (1 H, s), 7.80 (1 H, d, J = 8.4 Hz), 7.47 (1 H, d, J = 3.5 Hz), 7.22 (1 H, d, J = 3.5 Hz), 5.22 (1 H, d, J = 7.9 Hz), 4.52 (1 H, d, J = 8.3 Hz), 3.74 (1 H, m), 2.83 (1 H, m), 1.45 (3H, m), 0.96 (9H, s) 0.79 (3H, d, J = 6.2 Hz) and 0.72 (3H, d, J = 6.2 Hz). ~3C-NMR; b ((CD3)2S0), 172.9, 169.3, 168.7, 157.4, 137.6, 113.5, 71.3, 59.9, 47.4, 37.2, 34.1, 26.4, 25.2, 23.5 and 21.7.

3R-(2,2-Dimethyl-1 S-phE~nylcarb~amoyl-propylcarbamoyl)-2S-hydroxy-5-phenylhexanohydroxamic acid pGT/GB95/00111 O
_H - ,,.w H H
N N
H
/ .: O /
HO CONHOH
H
Mixture of diastereoisomers (4:1, SRS:RRS).
White solid. m.p. 98 °C. ~ H-NMR; b (CD30D) 7.55 - 7.47 (2H, m), 7.28 -7.21 (2H, m), 7.12 - 7.01 (6H, m), 4.47 - 4.44 (0.8H, m), 4.39 - 4.35 (0.2H, m), 4.26 (0.2H, d, J = 4.8 Hz), 4.06 (0.8H, d, J = 6.5Hz), 2.87 - 2.83 (1 H, m), 2.57 - 2.48 (2H, m), 1.81 - 1.52 (4H, m), and 'I .03 (9H, s). ~3C-NMR; 8 (CD30D), 175.7, 171.5, 171.3, 143.3, 139.2, 129.6, 129.4, 129.3, 126.7, 125.5, 121.8, 73.0, 70.1, 62.6, 51.0, 36.7, 35.6, 30.3, 27.3 and 23.1. Found: C 65.05, H 7.57, N 8.78%; C25HaaNsOs . 4.3 requires C 65.06%, H 7.5'7%, N 8.78%.

3R-(2,2-Dimethyl-1 S-(4,5-dimethylthiazol-2-ylcarbamoyl)-propylcarbamoyl)-2S-hydroxy-5-methylhexanohydroxarnic acid O
H ~ ~~~ H H
N S
N
H
HO - ~CONHOH O N
H
White solid. m.p. 191.5 - 192°C. ~ H-NMR; b ((CD3)2S0), 11.84 (1 H, s), 10.62 WO 95/19956 ~ ~ ~ ~ y ~ ~ PCT/GB95100111 (1 H, s), 8.87 (1 H, s), 7.T3 (1 H, d, J = 8.5 Hz), 5.23 (1 H, d, J = 7.9 Hz), 4.48 (1 H, d, J = 8.5 Hz), 3.70 (1 H, m), 2.79 (1 H, m), 2.49 (3H, s), 2.22 (3H, s), 1.41 (2H, m), 0.94 (10H, s and br m), 0.72 (3H,. d, J = 6.2 Hz) and 0.78 (3H, d, J = 6.2 Hz).
~3C-NMR; S ((CD3)pS0), 171.5, 167.6, 167.4, 151.7, 140.4, 117.4, 70.1, 58.6, 46.2, 35.9, 32.9, 25.1, 24.0, 22.2, 20.5, 12.9 and 8.9. IR (KBr disk), vm~
1654 and 1535 cm-~ .

3R-(2,2-Dimethyl-1 S-(4-~ethoxycarbonylmethylthiazol-2-ylcarbamoyl)-propyl-carbamoyl)-2S-hydroxy-5-methylhexanohydroxamic acid O
H ~ .~~~~H H
N~S
HO CONHOH O N
H
C02Et White solid. m.p. 104.5 - 110.5°C. ~ H-NMR; 8 ((CD3)2S0), 12.17 (1 H, s), 10.61 (1 H, s), 8.87 (1 H, s), 7.T5 (1 H, cl, J = 7.9 Hz), 6.97 (1 H, s), 5.23 (1 H, d, J = 7.9 Hz), 4.48 (1 H, d, J = 8.3 Hz), 4.06 (2H, q, J = 7.2 Hz), 3.67 (3H, m), 2.85 (1 H, m), 1.40 (2H, m), 1.18 (3H, t, J = 'l.0 Hz), 0.96 (10H, s and br m), 0.78 (3H, d, J =
6.3 Hz) and 0.72 (3H, d, J = 6.3 Hz). ~3C;-NMR; 8 ((CD3)2S0), 182.4, 178.9, 178.2, 166.6, 153.2, 119.9, 80.9, 69.8, X69.6, 56.9, 46.1, 45.9, 43.6, 35.9, 34.7, 33.0, 31.2 and 23.6. IR (KBr disc); vmaX 1735, 1644, 1549 cm-~. Found: C 51.44, H 7.06, N
11.14%; C2~ H34N40~S . ~0.2 H20 requires C 51.46, H 7.07, N 11.43%.

3R-(2,2-Dimethyl-1 S-(5-bromo-l;hiazol-2-ylcarbamoyl)-propylcarbamoyl)-2S-hydroxy-5-methylhexanohydroxamic acid O
,~~~ H H
~N N
H II S Br y O N
HO CONHOH
H
White solid. m.p. 196 - 198°C. ~ H-NMR; b ((CD3)2S0), 8.74 (1 H, s), 7.70 (1 H, d, J = 8.2 Hz), 7.41 (1 H, s), 5.09 (1 H, d, J = 6.3 Hz), 4.36 (1 H, d. J = 8.2 Hz), 3.63 3.52 (1 H, m), 2.73 - 2.60 (1 H, m), 1.35 - 1.14 (2H, m), 0.93-0.72 (1 H, m), 0.81 (9H, s), 0.65 (3H, d, J = 6.3 t-Iz) and 0.58 (3H, d, J = 6.3 Hz). ~3C-NMR; b ((CD3)2S0), 173.1, 170.0, 168.7, 157.7, 138.7, 101.7, 67.3, 59.9, 47.4, 37.2, 34.0, 26.4, 25.3, 23.5 and 21.8. IR (KBr ~jisc); v~,ax 3236, 2966, 1659 and 1534 cm-~.

3R-(2,2-Dimethyl-1 S-(4-phenyl-thiazol-2-ylcarbamoyl)-propylcarbamoyl)-2S-hydroxy-5-methylhexanohydroxamic acid O
H .~~~~H H
N~S
HO ~ - CON HOH O N
H Ph White solid. m.p. 158 - 1 ~60°C. ~H-NMR; b ((CD3)2S0), 8.74 (1 H, s), 7.80-7.64 WO 95/19956 ~ ~ $ PCT~GB95100111 (3H, m), 7.45 (1 H, s), 7.33-7.12 (3H, m), 4.42 (1 H, d, J = 8.3 Hz), 5.39 (1 H, d, J =
8.6 Hz), 2.77-2.63 (1 H, rn), 1.35/-1.16 (2H, m), 0.84 (9H, s), 0.94-0.73 (1 H, m), 0.67 (3H, d, J = 6.4 Hz) and 0.59 (3H, d, J = 6.4 Hz). ~3C-NMR; b ((CD3)2S0), 173.0, 169.8, 168.8, 157.4, 148.9, 134.3, 128.7, 127.7, 125.7, 108.1, 71.4, 60.1, 47.5, 37.2, 34.1, 26.5, 25.3, 23.5 and 21.8. IR (KBr disc); vmax 3310, 2956, 1653, 1541 cm-~. Found: C 55.69, H 6.82, N 11.15%; C23H32N4O5S . 1.1 H20 requires C
55.65, H 6.94, N 11.29%.

3R-(2,2-Dimethyl-1 S-(5-methyl- t ,3,4-thiadiazol-2-ylcarbamoyl)-propylcarbamoyl)-2S-hydroxy-5-methyfhexanohyd~roxamic acid O
.~~~H H
N S
N
H
HO '~CONHOH O N1 N
H
White solid. m.p. 159 - 161 °C. ~ H-NMR; 8 ((CD3)2S0), 8.73 (1 H, m), 7.69 (1 H, d, J
= 8.2 Hz), 5.10 (1 H, m), 4..38 (1 H, d, J = 8.0 Hz), 3.58 (1 H, m), 2.69 (1 H, m), 2.45 (3H, s), 1.36 - 1.12 (2H, nn), 0.94 - 0.73 1 H, m), 0.82 (9H, s), 0.65 (3H, d, J = 6.3 Hz) and 0.58 (3H, d, J = 6.3 Hz). ~3C-NMR; S ((C03)2S0), 173.1, 169.6, 159.4, 157.9, 71.3, 60.2, 47.4, 37.2, 34.0, 28.4, 25.3, 23.5, 21.8 and 14.7. IR (KBr disc);
vmax 3260, 2959, 1655, 1540 .and 1311 cm-~. Found: C 46.71, H 7.24 N 16.02%;
C»H29N505S . 1.2 H20 requires C 46.71, H 7.24, N 16.02%.

~ ~ s ~. ~ 7 a pCT1GB95100111 3R-(2,2-Dimethyl-1 S-(4-teri butylthiadiazol-2-ylcarbamoyl)-propylcarbamoyl)-hydroxy-5-methylhexanohydroxamic acid O
w ?~ ''~~ H N
N ~S
H O N
HO . CONHOH
H
White solid. m.p. 169 - 171 °C. ~ f~-NMR; 8 ((CD3)2S0), 8.73 (1 H, s), 7.60 (1 H, d, J = 8.3 Hz), 6.58 (1 H, s), 5.09 (1 H, d. J = 7.9 Hz), 4.34 (1 H, d, J = 8.3 Hz), 3.56 (1 H, dd, J = 8.3 Hz), 3.74 - 2.60 (1 H, m), 1.39 - 1.03 (2H, m), 1.11 (9H, s), 0.92 -0.70 (1 H, m), 0.82 (9H, s), 0.65 (3H, d, J = 6.3 Hz) and 0.58 (3H, d, J = 6.3 Hz).
~3C-NMR; 8 ((CD3)2S0), 172.9, 169.4, 168.7, 160.2, 156.7, 104.7, 71.4, 60.1, 47.4, 37.2, 34.1, 34.0, 29.13, 26.5, 25.2, 23.6 and 21.7. IR (KBr disc); vm~
3270, 2962, 1668, 1557, 1368, 1270 cm-~. Found: C 53.74, H 8.18, N 11.45%;
C2~ H36N405S. 0.9 H20 requires C 53.35, H 8.06, N 11.85%.
R-(2,2-Dimethyl-1 S-pyridin-2-ylcarbamoyl-propylcarbamoyl)-5-methyl-2S-propen-2-yl-hexanohydroxamic acrid o E~ ,,.v H H
N ~N
N
H O
CONHOH
H

WO 95119956 ~, PCT/GB95100111 T P A:
3R,S-Allyl-2R-isobutyl-butan-1,4-dioic acid-4-tert-butyl ester (1:9, RS:RR) To a stirred solution of 2R-isobutyl-1,4-dioic acid-4-tent butyl ester (5 g, 21.7 mmol) in dry THF (100 ml), und~ar an argon atmosphere, at -78°C, was added 1.5M LDA
(31.8 ml, 47.7 mmol) dropwise via cannula. After stirring the solution at -78°C for 1 hour, allyl bromide (2.44 ml, 28.2 mmol) was added dropwise via syringe. The resulting solution was allowed to warm to room temperature over a 2 hour period.
Methanol (10 ml) was added ands the solution stirred at room temperature.
After 30 minutes the reaction mixture was concentrated under reduced pressure. The residue was taken up in dichloromethane (100 ml) and washed with 1 M
hydrochloric acid (100 mI~) and brine (100 ml). The dichloromethane layer was dried over anhydrous ma~gnesiurn sulphate, filtered and solvent removed under reduced pressure to give the title compound as a golden oil (5.6 g, 97%) (1:9, RS:RR) ~H-NMR; 8 (CDC;13, major diastereoisomer), 5.78 - 5.63 (1 H, m), 5.01 -5.11 (2H, m), 2.57 - 2.72 (2H, rn), 2.37 (2H, m), 1.52 -1.67 (2H, m), 1.42 (9H, s), 1.37 (1 H, m) and 0.90 (6H, d, .J = 6.3 Hz). ~3C-NMR; S (CDC13, major diastereoisomer) 181.1, 172.9, 134.6, 117.3, 81.2, 47.8, 44.3, 38.4, 27.9, 25.9, 23.5, and 21.5.
STEP B:
3R,S-Allyl-2R-isobutyl-1,4.-dioic acid-4-terf butyl ester (3:1, RS:RR) (i) To a stirred solution of 3R.,S-allyl-2R-isobutyl-1,4-dioic acid-4-tert-butyl ester (1:9, RS:RR) (5.11 g, 18.51 mmol) in dry THF (100 ml) under argon at -78°C was added 1.5M LDA (27.7 ml, 41.6 mmol) via cannula. The reaction mixture was warmed to room temperature over a 2 hour period then cooled back to -78°C and methanol (8 ml) was addE~d via syringe. The reaction was then allowed to warm to room temperature for a further 2 hours. The solvent was removed under reduced pressure. The residue was taken up in dichloromethane (150 ml) and washed with 1 M hydrochloric acid (150 ml) and brine (150 ml). The dichloromethane layer was dried over anhydrous magnesium sulphate, filtered and the solvent removed under reduced pressure to yield the title compound (3:2, RS:RR), as a brown oil (4.7 g, 92%).
(ii) Utilising the epimerisation procedure described in Example 23B (i), but employing a reaction temperature of -78°C after addition of LDA in lieu of allowing the reaction mixture to warm to room temperature yielded the title compound, as the major diastereoisomer as a brown oil (4.6 g, 98%) (3:1, RS:RR). ~ H-NMR; 8 (CDC13, major diastereoisomer), 11.60 (1 H, br s), 5.75 - 5.61 (1 H, br m), 5.06 - 4.96 (2H, br m), 2.70 - 2.52 (2'H, br m), 2.36 - 2.19 (2H, br m), 1.65 - 1.44 (2H, br m), 1.40 (9H, s), 1.13 (1 H, m) and 0.86 (E',H, dd, J = 4.4, 2.1 Hz). ~3C-NMR; b (CDC13, major diastereoisomer) 180.7, 172.2, 134.6. 1 17.1, 81Ø 48.6, 45.7, 38.9, 34.8, 33.4, 27.9, 26.2 and 21.2.
TEP
3R,S-Allyl-2R-isobutyl-1,4-dioic acid-1-pentafluorophenyl-4 tent-butyl diester (3:1, RS:RR) To a stirred solution of 3R,S-allyl-2R-isobutyl-1,4-dioic acid-4 ten-butyl diester (4.60 g, 17.2 mmol) (3:1, RS:FIR) in dichloromethane (50 ml) was added pentafluorophenol (6.13 g, 33.3 mmol). The reaction mixture was cooled to 0°C
and NMM (2.02 g, 20.0 nnmol) and EDC (3.94 g, 20.0 mmol) were added. The reaction mixture was allowed to warm to room temperature and stirred for 12 hours.
The solvent was removed under reduced pressure. The residue was taken up in dichloromethane (50 ml) and washed with 1 M hydrochloric acid (3 x 50 ml), saturated sodium hydrogen carbonate (3 x 50 ml) and brine (50 ml). The dichloromethane layer was dried over anhydrous magnesium sulphate, filtered and the solvent removed under reduced pressure to give a brown oil. Column chromatography (silica gel, dichloromethane) yielded the title compound as a WO 95/19956 ~ ~ ~ PCT/GB95100111 golden oil (5.47 g, 74%) (3:1, RS:SR). b (COC13, major diastereoisomer), 5.85 -5.67 (1 H, br m), 5.17 - 5.05 (2H, br m), 3.10 - 3.01 (1 H, m), 2.79 - 2.69 (1 H, m), 2.51 - 2.29 (2H, br m}, 1.88-1.61 (2H, br m), 1.46 {9H, s), 1.37-1.24 (1 H, m) and 0.96 (6H, dd, J = 4.0, 4.5 Hz). ~3C~~NMR; 8~ (CDC13, major diastereoisomer}, 171.5, 170.3, 134.1, 117.5, 81.4, 48.8, 45.8, 39.5, 35.0, 27.9, 26.3, 23.5, and 21Ø
TS EP D:
L-tent leucine-2-pyridylarnide The title compound was prepared from Na-benzyloxycarbonyl-L-iert-leucine by methods analogous to those described in Example 1 (Steps D and E). ~ H-NMR; b (CDC13), 8.26 (1 H, m). 8. ? 0 (1 H. m). 7.74 (1 H. m), 7.06 (1 H, m), 3.25 (1 H, s), 1.00 (9H, s).
T P
3R-(2,2-Dimethyl-1 S-pyridin-2-ylcarbamoyl-propylcarbamoyl)-5-methyl-2S-propen-2-yl-hexanoic acid-1-teri-butyl ester The products from 3R,S-allyl-2R-isobutyl-1,4-dioic acid-1-pentafluorophenyl-4 Pert butyl diester (3:1, RS:RR) (5.59 c,~, 12.8 mmol) and L-tert leucine-2-pyridylamide (2.91 g, 14.1 mmol) were dissolved together in DMF (50 ml) and stirred at 30°C for 40 hours. TLC revealed that all of the pentafluorophenyl ester had been consumed. The solvent 'was removed and the residue was purified by column chromatography {silica gel, ethyl acetate-hexane, 1:1 ) and crystallisation from ethyl acetate-hexane. Yield: 1.41 g (24%, 5:1 mixture of SRS:RRS diastereoisomers).
~ H-NMR; b (CDC13, major diastereoisomer}, 9.58 (1 H, m), 8.52 (1 H, m), 8.19 (1 H, d, J = 8.3 Hz), 7.73 {1 H, m), 7.12 (1 H, m), 6.49 (1 H, d, J = 9.2 Hz), 5.76 (1 H, m), 5.05 (1 H, m), 4.62 (1 H, d, J = 9.2 Hz), 2.68 (1 H, m), 2.53 {1 H, m), 2.29 (2H, m), 1.73 (1 H, m), 1.47 (1 H, m), 1.45 (9H, s), 1.15 (1 H, m), ?.02 (9H, s), 0.87 (3H, d, J =
6.5 Hz) and 0.79 (3H, d, J = 6.5 Hz).
STEP F:
3R-(2,2-Dimethyl-1 S-pyridin-2-ylcarbamoyl-propylcarbamoyl)-5-methyl-2S-propen-2-yl-hexanoic acid 3R-(2,2-Dimethyl-1 S-pyridin-2-ylcarbamoyl-propylcarbamoyl)-5-methyl-2S-propen-2-yl-hexanoic acid -1-ten! butyl ester (1.74 g, 3.78 mmol) was deprotected by TFA acidolysis according to the method described in Example 1 (Step G), affording the title compound contaminated with residual TFA. Yield: 1.61 g (contains solvent), 5:1 mixture of diastereoisomers. ~H-NMR; b (CD30D, major diastereoisomer). 8.29 (1 H, m), i .90 (2H, m). 7.23 (1 H, m), 5.72 (1 H, m), 4.99 (2H, m), 4.46 (1 H. s). 2.80 (1 H, dt. J = 3.3, 10.8 Hz), 2.52 (1 H, dt, 4.3. 10.2 Hz), 2.40 -2.12 (2H, br m), 1.62 (1 H, m), 1.42 (1 H, m), 1.10 (2H, m), 1.08 (9H, s), 0.86 (3H, d, J
= 6.5 Hz) and 0.75 (3H, d, J = 6.6 Hz).
STEP G
3R-(2,2-Dimethyl-1 S-pyridin-2-ylcarbamoyl-propylcarbamoyl)-5-methyl-2S-propen-2-yl-hexanohydroxamic acid 3R-(2,2-Dimethyl-1 S-pyridin-2-ylcarbamoyl-propylcarbamoyl)-5-methyl-2S-propen-2-yl-hexanoic acid (1.5 g, 3.71 mmol) was dissolved in DMF (5 ml) and the solution was cooled to 0°C during the addition of HOBt (0.60 g, 4.46 mmol) and EDC (0.86 g, 4.46 mmol). The mixture was stirred at 0°C for 1 hour then at room temperature for 2 hours to ensurs~ complete formation of the active ester. The solution was cooled back to 0°C, hydroxylamine hydrochloride (0.39 g, 5.57 mmol) was added followed by NIV1M (0.56 g, 5.57 mmol) and the reaction mixture was allowed to warm to room temperature then stirred overnight. The solvent was removed in vacuo and the residue was triturated with a mixture of diethyl ether (25 ml) and water (25 ml) and left to stand for 2 hours. The resulting solid was WO 95119956 ~ ~. ~ ~. ~ !~ ~ PCT/GB95100111 collected by filtration, recrystallised from methanol-DIPE and dried under high vacuum at 60°C for 24 hours to ,afford the title compound (0.62 g, 40%;
single diastereoisomer) containing ca. 0.4 mol DIPE (NMR). m.p. 221 - 223°C.
~H-NMR;
8 (CD30D), 8.26 (1 H, m), 8.04 (1 H, d, J = 8.3 Hz), 7.72 (1 H, dt, J = 1.9, 5.5 Hz), 7.07 (1 H, m), 5.64 (1 H, m), 4.96 (2H, m), 4.52 (1 H, s), 2.72 {1 H, m), 2.26 (2H, m), 2.10 (1 H, m), 1.50 (1 H, m), 1.39 (1 H, m), 1.06 (9H, s), 1.07 (1 H, m), 0.84 (3H, d, J =
6.4 Hz) and 0.73 (3H, d, J = 6.5 I-iz). ~3C-NMR; 8 (CD30D), 176.8, 172.4, 171.4, 152.7, 149.1, 139.4, 136.0, 121.1, 117.5, 115.7, 63.1, 48.2, 47.8, 41.8, 36.4, 35.3, 27.3, 27.0, 24.4 and 21.9. Found: C 63.68, H 8.66, N 12.08%; C22H34N4O4 . 0.4 C6H~40 requires: C 63.79, H 8.69, N 12.20%.
The following additional compounds were prepared according to the methods of Example 23:

3R-(2,2-Dimethyl-1 S-phenylcarbamoyl-propylcarbamoyl)-5-methyl-2S-propen-2-yl-hexanohydroxamic acid O
H .,.w H N
N
_ H O
CONHOH
H
White solid. m.p. 211.5-;?12.5°C. ~H NMR; 8 (CD30D), 7.45 (2H, m), 7.26 (2H, m), 7.05 (1 H, m), 5.66 (1 H, m), 4.9Ei (2H, m), 4.46 (1 H, s), 2.73 (1 H, m), 2.26 (2H, m), 2.11 (1 H, m), 1.49 (1 H, m), 1.48 (1 H, m), 1.08 (1 H, m), 1.06 (9H, s), 0.84 (3H, d, J
= 6.4 Hz) and 0.75 (3H, d, J = 6.5 Hz). ~3C- NMR; 8 (CD30D), 176.7, 173.0, 171.0;

WO95/19956 ~~~~-~n~~

139.3, 136.1, 129.8, 125.8, 121.6, 117.5, 62.9, 48.2, 41.8, 36.4, 35.4, 27.3, 27.1, 24.4 and 21.9. Found: C 63.68, IH 8.55 N 9.69%; C23H35N3O4 . 0.9 H20 requires C
63.69, H 8.55, N 9.69%.
3R-(2,2-Dimethyl-1 S-(thiazol-2-ylcarbamoyl)-propyicarbamoyl)-5-methyl-2S-propen-2-yl-hexanohydroxamic acid O
H ,av H N
H II S
O N
CONHOH
H
White solid. m.p. > 300°C. ~H-NIVIR; S ((CD3)2S0), 12.10 (1 H, s), 10.46 (1 H, s), 8.77 (1 H, s), 8.12 (1 H, d, J = 7.9 Hz), 7.45 (1 H, d, J = 3.5 Hz), 7.20 (1 H, d, J = 3.5 Hz), 5.62 (1 H, m), 4.93 (2H, m), 4.51 (1 H, d, J = 4.5 Hz), 2.82 (1 H, m), 2.30 (1 H, m), 2.22 (2H, m), 1.41 (3H, m), 0.98 (9H, s), 0.88 (3H, d, J = 6.3 Hz) and 0.78 (3H, d, J = 6.3 Hz). ~3C-NMR; b ((CD;3)2S0), 174.1, 169.3, 169.2, 157.4, 137.7, 135.8, 116.2, 113.5, 60.3, 45.9, .45.3, 40.2, 34.9, 33.5, 26.5, 25.2, 24.0 and 21.7.
Found:
C 56.30%, H 7.70% N 12.70%; C2pH32N404S . 0.2 H20 requires C 56.10%, H
7.63% N 13.09%.

3R-(2,2-Dimethyl-1 S-(4-rnethoxyphenylcarbamoyl)-propylcarbamoyl)-5-methyl-2S-propen-2-yl-hexanohydroxamic acid WO 95/19956 PCT/GB95/00111 '-'~
218~:'~7t~

O
H ~ .,~~~H H
N N \
H I
H ~CONHOH O ~ OMe White crystaline solid. m.p. 213 ~- 228°C. ~ H-NMR; b (CD30D), 8.13 (1 H, d, J = 9.0 Hz), 7.33 (2H, d, J=9.0 I-iz), 6.8'1 (2H, d, J = 9.0 Hz), 5.63 (1 H, m), 4.97 {2H, m), 4.45 (1 H, t, J = 5.4, 3.6 Hz), 3.72 (3H, s), 2.73 (1 H, m), 2.20 (3H, m), 1.43 (2H, m), 1.10 (1 H, m), 1.06 (9H, ~;), 0.84 (3H, d, J = 6.4 Hz), and 0.75 (3H, d. J =
6.5 Hz).
~3C-NMR; 8 (CD30D), 176.7, 172.4, 170.8. 158.1, 136.0, 132.1, 123.5, 117.5, 115.0, 62.9, 55.9, 48.1, 41.9, 36.4. 35.4. 27.4. 27.1, 24.4 and 22Ø IR (KBr disc); v max 3308, 2958, 1644. 1513, 1245, 1036 and 830 cm-~. Found C 63.39, H 8.26, N
9.30%. C24H3~N305 . 0.4 H20 requires C 63.39, H 8.38, N 9.24%.

3R-(2-Benzylthio-2-methyl-1 S-(pyridin-2-ylcarbamoyl)-propylcarbamoyl)-5-methyt-2S-propen-2-yl-hexanohydroxamic acid I
O S
H .aH N N
I W
CONHOH O
H

White solid. m.p. 214 - 214.5°C. ~ H-NMR; 8 (CD30D at 338 K), 8.36 (1 H, m), 8.02 (1 H, m), 7.72 (1 H, m), 7.32 - 7.12 (5H, br m), 7.05 (1 H, m), 5.62 - 5.53 (1 H, br m), 4.96 - 4.82 (3H, br m), 3.87 (2H, s), 2.69 (1 H, m), 2.37 - 2.21 (3H, m), 1.61 - 1.34 (2H, br m), 1.51 (3H, s), 1.45 (3H, s), 1.13 (1 H, br m), 0.82 (3H, d, J = 6.4 Hz) and 0.73 (3H, d, J = 6.4 Hz). ~3C-NMR; 8 ((CD3)2S0), 172.8, 168.1, 167.9, 146.8, 136.9, 136.4, 134.9, 128.0, 127.0, 125.4, 118.4, 114.7, 112.5, 56.5, 47.2, 44.8, 44.4, 33.6, 31.2, 25.3, 24.2, 22.7, 22.64 and 20.4.

3R-(2,2-Dimethyl-1 S-(pyridin-3-ylcarbamoyl)-propylcarbamoyl)-5-methyl-2S-propen-2-yl-hexanohydroxamic acid .,~~ H N
~N
NHOH ~
White solid. m.p. 220 - 224°C. ~ H-NMR; b ((CD3)2S0), 10.30 (1 H, s), 10.00 (1 H, s), 8.73 (1 H, s), 8.26 (1 H., d, J = 4.1 Hz), 7.99 (1 H, d, J = 8.2 Hz), 7.81 (1 H, d, J =
8.5 Hz), 7.34 (1 H, m), 5.E~5 (1 H, rn), 4.93 (2H, m), 4.43 (1 H, d, J = 5.3 Hz), 2.74 (1 H, m), 2.50 - 2.21 (3H, rn), 1.SCI (3H, m), 1.04 (9H, s), 0.83 (3H, d, J =
6.4 Hz), and 0.77 (3H, d, J = 6.3 H:z). ~3C-NMR; 8 ((CD3)2S0), 174.0, 169.7, 169.2, 144.2, 140.7, 135.8, 135.4, 126.1), 123.6, 116.1, 61.0, 45.9, 45.5, 34.9, 33.7, 26.6, 25.3, 24.0 and 21.7.

WO 95119956 ~ ~ ~ ~ PCT/GB95100111 '"' 3R-(2,2-Dimethyl-1 S-(4-hydroxyphenylcarbamoyl)-propylcarbamoyl)-5-methyl-2S-propen-2-yl-hexanohydroxamic acid O
H .~~~~ H H
\ _~ N N \
H O I /
H CONHOH OH
Yellow solid. ~ H-NMR; 8 ((CD3)2S0), 10.46 (1 H, s), 9.70 (1 H, s). 9.17 (1 H, s), 8.77 (1 H, s), 8.00 (1 H, d, J = E1.7 Hz), 7.31 (2H, d, J = 8.8 Hz), 6.70 (2H, d, J
= 8.8 Hz), 5.67 (1 H, m), 4.93 (2H, m), 4.38 (1 H, d, J = 8.7 Hz), 2.70 (1 H, m), 2.31-2.19 (3H, m), 1.44 (3H, m), 0.98 (9H, s), 0.81 (3H, d, J = 6.3 Hz) and 0.73 (3H, d, J = 6.3 Hz).
~3C-NMR; 8 ((CD3)2S0)" 173.8, 169.3, 168.4, 153.3, 135.9, 130.4, 121.0, 116.1, 114.9, 60.8, 45.8, 45.7, 3.4.9, 33.9, 26.7, 25.3, 24.0 and 21.7.

3R-(2,2-Dimethyl-1 S-(3-;methoxyphenylcarbamoyl)-propylcarbamoyl)-5-methyl-2S-propen-2-yl-hexanohydroxamic .acid O
H ~ ,,,~vH N OMe N \
H I
CONHOH O /
H

WO 95/19956 ~ . PCTIGB95J00111 White solid. ~ H-NMR; 8 ((CD3)2:50), 10.45 (1 H, s), 9.96 (1 H, s), 8.77 (1 H, s), 7.99 (1 H, d, J = 8. Hz), 7.40 (1 H, s), 7.26 (2H, m), 6.60 (1 H, d, J = 7.8 Hz), 5.60 (1 H, m), 4.93 {2H, m), 4.40 (1 H, d, J = 8.5 Hz), 3.72 (3H, s), 2.81 (1 H, m), 2.10 -2.49 (2H, m), 1.99 (1 H, m), 1.44 (;2H, m), 1.09 (9H, s), 0.99 (1 H, m), 0.82 (3H, d, J
= 6.3 Hz) and 0.72 (3H, d). ~3C-NMR; b ((CD3)2S0), 173.9, 169.3, 159.5, 140.0, 135.9, 129.5, 116.2, 111.6, 1 Oi3.5, 105.1, 61.1, 55.0, 45.9, 45.6, 40.3, 34.9, 33.9, 26.7, 25.3, 24.1 and 21.7.

3R-(2,2-Dimethyl-1 S-(p~yridin-4-ylcarbamoyl)-propylcarbamoyl)-5-methyl-2S-propen-2-yl-hexanohydroxamic acid H
,av H
N N \
H O ~ iN
~NHOH
Pale pink solid. m.p. 210°C (dec:.). ~H-NMR; 8 ((CD3)2S0), 10.15 (2H, s), 8.28 (2H, d, J = 3.9 Hz), 7.73~ (1 H, d, J = 8.1 Hz), 7.44 (2H, d, J = 5.1 Hz), 5.51 (1 H, m), 4.81 (2H, m), 4.26 (1 H, d, J = 8.~4 Hz), 2.75 (1 H, m), 2.36 (2H, m), 2.11 (1 H, m), 1.24 (2H, m), 0.88 (9H, s), 0.84 (1 H, m), x.68 (3H, d, J = 6.4 Hz) and 0.59 (3H, d, J
= 6.4 Hz). ~3C-NMR; b ((CD3)2S0), 172.8, 169.3, 167.9, 148.6, 144.3, 134.5, 114.8, 111.9, 60.1, 44.E~, 44.1, ;33.6, 32.3, 25.2, 23.9, 22.7 and 20.3.

WO 95/19956 PCT/GB95/00111 ~'°

3R-(2,2-Dimethyl-1 S-(2-rnethoxyphenylcarbamoyl)-propylcarbamoyl)-5-methyl-2S-thien-2-ylsulfanylmethyl-hexanohydroxamic acid OMe H .,~~~H H
N N \
H
CONHOH O
S
T P A' 2-Benzyloxycarbonyl-3R-(2,2-dimethyl-1 S-(2-methoxyphenylcarbamoyl)-propylcarbamoyl)-5-methyl-hexanohydroxamic acid benzyl ester 2-Benzyloxycarbonyl-3R-~;,arboxy-5-methylhexanoic acid benzyl ester (prepared by the method described in E:P 0 446 267) (20.1 g, 50.5 mmol) and L-Pert-leucine-N~-(2-methoxyphenyl)amide (prepared according to the method described in Example 1, Steps D and E) (14.3 g, 60.6 mmol) were dissolved together in ethyl acetate (300 ml). HOBt (8.2 g, 60.6 mrnol) anc! EDC (11.6 g, 60.6 mmol) were added and the mixture was stirred and h~aated at reflux overnight, after which TLC analysis showed that the reaction was cornplete. The solution was cooled and washed successively with 5% aq. sodium hydrogen carbonate (2 x 200 ml), 5% citric acid (2 x 200 ml) and brine (1 x 2'00 mi), dried over anhydrous magnesium sulphate, filtered and evaporated to give a brown oil (32.75 g, contained residual solvent) which was used in Step B without further purification. ~H-NMR; 8 (CDC13), 8.07 (1 H, s), 7.40 - 7.22 (10H, br m), 7.15 (1 H, m), 6.96 (1 H, m), 6.75 (1 H, m), 6.65 (1 H, m), 5.12 - 5.04 (3H, br m), 4.37 (1.H, d, J = 9.0 Hz), 3.85 (1 H, d, J = 9.6 Hz), 3.76 (3H, s), 3.08 (1 H, m), 1.80 - 1.37 (3H, br m), 1.06 (9H, s), 0.79 (3H, d, J =
6.4 Hz), 0.71 (3H, d, J = 6.5 Hz).
T P
3R-(2,2-Dimethyl-1 S-(2-methoxyphenylcarbamoyl)-propylcarbamoyl)-2-methylene-5-methyl-hexanohydroxamic acid 2-Benzyloxycarbonyl-3R-(2,2-dimethyl-1 S-(2-methoxyphenylcarbamoyl)-propylcarbamoyl)-5-methyl-hexanohydroxamic acid benzyl ester (28.7 g, 45.40 mmol) was dissolved in ethanol (200 ml) and the solution was placed under a blanket of argon. 10% F~alladiunn on charcoal was added and a fine stream of hydrogen gas was passE~d through the suspension for 3h with stirring. TLC
showed that all the starting material had been consumed. The system was purged with argon and the catalyst was removed by filtration. The filtrate was cooled and stirred in an ice bath and treatecl with piperidine (4.04 g, 47.4 mmol) which was added dropwise, followed by 37~% formaldehyde solution (32.3 ml, ca. 430 mmol).
The reaction mixture wa;~ allowed to warm slowly to room temperature, then stirred overnight. The solvents were removed under reduced pressure and the residual oil was partitioned betwE~en ethyl acetate (300 ml) and 1 M hydrochloric acid (300 ml). The organic layer Nras separated, washed with 1 M hydrochloric acid and brine, dried over magnesium sulphate and evaporated to dryness. The remaining pale brown foam (18.94 g, crude) contained a number of minor impurities but was used in Step C without purification. ~ H-NMR; 8 (CD30D), 7.55 (1 H, m), 7.09 (3H, m), 6.95 (1 H, m), 6.59 (1 H, m), 6.26 (1 H, s), 5.72 (1 H, s), 4.30 (1 H, d, J = 9.2 Hz), 3.67 (1 H, s), 3.65 (1 H, m), 1.70 (1 H, m), 1.41 (2H, m), 0.91 (9H, s), 0.81 (3H, d, J =
6.3 Hz), 0.76 (3H, d, J = 6.3 Hz).
T P
3R-(2,2-Dimethyl-1 S-(2-~methoxyphenylcarbamoyl)-propylcarbamoyl)-5-methyl-2S-thien-2-ylsulfanylmethyl-hexanoic acid 21$~.~i0 3R-(2,2-Dimethyl-1 S-(2-~methoxyphenylcarbamoyl)-propylcarbamoyl)-2-methyiene-5-methyl-hexanohydroxamic acid (20.43 g, 48.7 mmol) was dissolved in methanol and placed under a blanket of argon prior to addition of 2-mercaptothiophene (20 ml). The mixture was stirred overnight at 60°C under argon with the exclusion of light. The solvent was removed under reduced pressure to leave an oil to which was added cold diethyl Ether (2170 ml). The product precipitated on standing in an ice bath and was removed by fil~~tration and washing with thoroughly with cold diethyl ether. The product was further purified by trituration with hot ethyl acetate and column chromatography (silica gel, gradient elution, 0-X20% methanol in dichloromethane). Fracl;ions were combined and evaporated to yield the title compound as an off-white foam (18.80 g. 72%). ~ H-NMR; b (CDC13), 7.33 (1 H, m), 7.14 - 7.09 (2H, m), 7.10 (1 H, m), 6.95 - 6.85 (2H, br m), 6.58 (1 H, m), 4.31 (1 H, s), 3.66 (3H, s), 2.99 - 2.58 (4H, br m), 1.60 - 1.48 (1 H, m), 1.37 - 1.18 (1 H, m), 1.01 (1 H, m), 0.95 (9H, s), 0.75 (3H, d, J = 6.5 Hz), 0.68 (3H, d, J = 6.5 Hz).
STEP D:
3R-(2,2-Dimethyl-1 S-(2-methoxyphenylcarbamoyl)-propylcarbamoyl)-5-methyl-2S-thien-2-ylsulfanylmethyl-hexanohydroxamic acid To a ice-cooled solution of 3R-(2,2-dimethyl-1 S-(2-methoxyphenylcarbamoyl)-propylcarbamoyl)-5-methyl-2S-thien-2-ylsulfanylmethyl-hexanoic acid (20.43 g, 38.1 mmol) in DMF (100 ml) was added HOBt (6.18 g, 45.7 mmol) followed by EDC
(8.77 g, 45.7 mmol). The mixture was stirred at 0°C for 1 h then at room temperature for a further 2h, cooled back to 0°C and treated with hydroxylamine hydrochloride (3.97 g, 5i'.2 mmol) and NMM (5.78 g, 57.2 mmol). The reaction mixture was stirred overnight at room temperature then evaporated to an oil which was triturated with 1:1 diethyl ether / water (240 ml) and left to stand for 1.5 h. The resulting precipitate was collected by filtration and washed thoroughly with cold diethyl ether. HOBt was removed by crystallisation from ethyl acetate and the WO 95/19956 c~ PCTlGB95/00111 mother liquors were evaporated to give the title compound as an orange foam (4.96 g, 24%). m.p. 191 ~~ 195°C. ~ H-NMR; b (CD30D), 8.07 (1 H, d, J =
8.8 Hz), 7.31 (1 H, m), 7.11 (2H, rn), 7.02 (1 H, m), 6.92 (1 H, m), 6.86 (1 H, m), 6.56 (1 H, m), 4.28 (1 H, m), 3.66 (3H, s), 3.00 (1 H, m), 2.75 (1 H, m), 2.62 (1 H, m), 2.35 (1 H, m), 1.43 (1 H, m), 1.26 {1 H, rn), 1.03 {1 H, m), 0.94 (9H, s), 0.75 (3H, d, J =
6.4 Hz) and 0.67 (3H, d, J = 6.6 Hz). ~3C-NMR; 8 ((CD3)2S0), 176.2, 171.2, 165.4, 161.9, 140.8, 135.2, 131.0, 130.9, 128.0, 114.0, 111.3, 107.7, 63.4, 56.0, 46.2, 42.0, 40.8, 35.8, 27.7, 27.4, 24.7 and 22.2. IR (KBr disk) vmax 3294, 3087, 2959, 1771, 1644, 1547, 1493, 1466, 1430, 1386 and 1369 cm-1. Found: C 57.80, H 6.99, N 7.74%;
C26H3~NZOSS2 . 0.3H20 ~~equires C 57.71, H 7.00, N 7.77%.
The following additional compound was prepared according to the methods of Example 32:

3R-(2,2-Dimethyl-1 S-(pyridin-2-ylcarbamoyl)-propylcarbamoyl)-5-methyl-2S-thien-2-ylsulfanylmethyl-hexanohydroxamic acid O
H .,a~H N N
CONHOH O
S S
White crystalline solid. m.p. 199 - 200°C. ~H-NMR; S ((CD3)2S0), 8.82 (1 H, s), 8.15 (1 H, m), 7.89 (1 H, rn), 7.86. (1 H, m), 7.60 (1 H, m), 7.44 (1 H, m), 6.93 (2H, m), 6.87 (1 H, m), 4.36 (1 H, d, J = 8.3 Hz), 3.04 {1 H, m), 2.75 (1 H, m), 2.56 (1 H, m), 2.22 (1 H, m), 1.29 (1 H, rn), 1.12' (1 H, m), 0.90 (1 H, m), 0.82 (9H, s), 0.65 (3H, d, J

WO 95/19956 ~ ~ ~ ~ ~ PCTIGB95/00111 = 6.4 Hz) and 0.55 (3H., d, J = 6.5 Hz). ~3C-NMR; b ((CD3)2S0), 173.1, 170.0, 167.9, 151.5, 148.0, 138.0, 133.8, 132.6, 129.6, 127.8, 119.3, 113.6, 60.7, 48.6, 46.0, 45.6, 33.6, 26.6, 25.2, 23.9 and 21.5. IR (KBr diSC); vrt,ax 3256, 2890, 2871, 1651, 1579, 1520, 146E~, 1435, 1369, 1298, 1217, 1152, 1054 and 1002 cm-~ .

3R-(2,2-Dimethyl-1 S-(2-methoxyphenylcarbamoyl)-propylcarbamoyl)-5-methyl-2S-thien-2-ylsulfinylmethyl-hexanohydroxamic acid O OMe H .,~~~ H H
N N \
" O ~ i ~CONHOH
~S ,OOH
3R-(2,2-Dimethyl-1 S-(2-methoxyphenylcarbamoyl)-propylcarbamoyl)-5-methyl-2S-thien-2-ylsulfanylmethyl-hexanohydroxamic acid (prepared in Example 32) (1.00 g, 1.81 mmol) was dissolved in methanol (20 mi) and cooled to 0°C in an ice bath during addition of mCPE3A (0.34. g, 2.00 mmol). The reaction mixture was allowed to warm to room temperature, stirred for 4 h, and the solvent was removed under reduced pressure. The residue was triturated with diethyl ether leaving the crude product as a solid which was co~ilected by filtration. Recrystallisation from ethyl acetate afforded the title compound as a white powder in two crops (304 mg, 30%).
m.p. 210 - 211 °C. ~ H-NMR; 8 (CD30D), 7.31 (1 H, m), 7.01 (2H, m), 7.00 (1 H, m), 6.81 (1 H, m), 6.80 (1 H, rn), 6.56 (1 H, m), 4.29 (1 H, s), 3.65 (3H, s), 2.95 (1 H, m), 2.73 (1 H, m), 2.63 (1 H, rn), 2.37 (1 H, m), 1.43 (1 H, m), 1.26 (1 H, m), 1.05 (1 H, m), 0.95 (9H, s), 0.75 (3H, d, J = 6.4 Hz) and 0.68 (3H, d, J = 6.5 Hz). ~3C-NMR;

(CD30D), 175.5, 170.7, 170.6, 161.1, 140.0, 134.5, 130.3, 130.2, 128.2, 113.3, WO 95/19956 ~ PCT/GB95/00111 110.6, 107.0, 62.6, 55.3, 41.3, 40.1, 35.1, 27.0, 26.7, 24.0 and 21.5. IR (KBr disc) vmax 3292, 1614, 1538, 1489, 1428, 1371, 1232, 1170 and 1047 cm-~. Found: C
55.70, H 6.68, N 7.39%; C26H3~P~306S2 . 0.5 H20 requires C 55.69, H 6.83, N
7.49%.
The following additional c:ompou~nd was prepared according to the methods of Example 34:

3R-(2,2-Dimethyl-1 S-(pyridin-2-ylcarbamoyl)-propylcarbamoyl)-5-methyl-2S-thien-2-ylsulfinylmethyl-hexanohydroxamic acid O
H ,,.~~H N N
H
CONHOH C
S S,D
White powder. m.p. 166 -166.5°C. ~H-NMR; 8 ((CD30D), 8.18 {1 H, m), 7.94 (1 H, m), 7.82 (1 H, m), 7.64 (1 H, m), 7.50 (1 H, m), 7.10 (1 H, m), 7.00 (1 H, m), 4.42 (1 H, m), 3.53 (1 H, m), 2.99 (1 H, m), 2.77 (1 H, m), 2.19 (1 H, m), 1.53 (1 H, m), 1.34 (1 H, m), 1.13 (1 H, m), 0.98 (9H, s), 0.77 (3H, m), and 0.66 (3H, m). ~3C-NMR; 8 ((CD30D), 175.4, 171.2, 169.9, 1'~ 52.7, 149.2, 144.8, 139.4, 134.2, 133.5, 128.6, 121.1, 115.6, 63.2, 61.2, 59.8, 4;3.2, 41.2, 35.3, 27.4, 27.0, 24.3 and 21.8.
IR (KBr disc); vmax 3259, 2959, 1647, 1578, 1529, 1467, 1435, 1369, 1297, 1224, 1152 and 1034 cm-~. Found: C 53.ti4, H 6.:52 N 10.33%; C24HsaNaOsS2 . 0.8 H20 requires C
53.67, H 6.68, N 10.43%.

PCTlGB95/00111 3R-(2,2-Dimethyl-1 S-phenylcarbamoyl-propylcarbamoyl)-2S-hydroxy-5-phenylhexanoic acid O
H .,~~~ H H
/ N N \
\ I H O I /

H
A solution of N2-[2R-(2,'.2-dimethyl-4-oxo-1,3-dioxalan-5S-yl)-6-phenylhexanoyl)-L-tert leucine-N~-phenylarnide (prepared by a method analogous to that described in Example 4) (1.00 g, 2.08 mmol) in THF (15 ml) was cooled to 0°C
and 1 M
hydrochloric acid (15 ml) was added. The mixture was stirred at room temperature until TLC indicated that all of the starting material had been consumed (several days). The solvents were removed under reduced pressure to leave a pale yellow foam which was dissolved in ethyl acetate and filtered through a pad of silica. The product was purified further by extraction into 1 M sodium carbonate solution, re-acidification with 1 M hydrochloric acid and back extraction into ethyl acetate. The ethyl acetate layer was dried over magnesium sulphate, filtered and evaporated under reduced pressure to afford the title compound as an off-white foam (320 mg, 35%; 3:1 mixture of dias~tereoisomers). m.p. 159°C. ~ H-NMR; 8 (CD30D), 7.51 -7.48 (2H, m), 7.26 - 7.00 (8H, m), 4.39 (1 H, s), 4.25 (0.25H, d, J = 3.7 Hz), 4.18 (0.75 H, d, J = 2.7 Hz), 2.90 (1 H, br s), 2.56 - 2.51 (2H, br m), 1.74-1.56 (4H, m), and 1.02 (9H, s). ~3C-NMR; 8 (CD30D), 179.3, 176.9, 171.1, 143.4, 139.2, 129.7, 129.4, 129.3, 126.7, 125.5, 121.8, 73.6, 63.1, 50.9, 36.6, 35.6, 30.5 and 27.4.
Found: C 66.07, H 7.21, N 5.98%: C25Hs2N20s . 0.8H20 requires C 66.00, H 7.44, N
6.16%.

3R-(2,2-Dimethyl-1 S-pyridin-2-ylcarbamoyl-propylcarbamoyl)-5-methyl-2S-phthalimidomethylhexanohydroxamic acid O
H ,~~~ H H
N N
H
CONHOH O
H
O N, O
TS EP A:
2-Benzyloxycarbonyl-3R-tent-butoxycarbonyl-5-methyl-2-phthalimidomethyl-hexanoic acid benzyl e:>ter To an ice-cooled solution of 2-benzyloxycarbonyl-3R-tert-butoxycarbonyl-5-methylhexanoic acid benzyl ester (prepared by the method described in EP 0 446 267) (39.4 g, 86.78 mm~ol) in dr'y DMF (400 ml) was added sodium hydride (60%
dispersion in mineral oil, 3.83 g, 95.46 mmol) with stirring. The reaction mixture was maintained at 0°C for 20 rains then allowed to warm to room temperature and stirred for a further 2.5 h. After cooling to 0°C, N-bromomethyl)phthalimide (25 g, 104.1 mmol) was added and the mixture was stirred for 0.5 h at 0°C then at room temperature overnight. The soilvent was removed under reduced pressure to leave an oil which was extracted with diethyl ether (400 ml) and the solid residues were removed by filtration. The filtrate was washed successively with water (300 ml), 1 M

PCT/GB95/00111 "' W095119956 ~1~1~~~
hydrochloric acid (300 ml) and brine (300 ml), dried over anhydrous magnesium sulphate and filtered. The solution was concentrated in vacuo to leave a yellow oil which was purified by column chromatography (silica gel, 50% diethyl ether in hexane) to afford the title compound as a colourless oil (26.24 g, 49%). ~ H-NMR; 8 (CDC13), 7.78 (2H, m), 7.Ei7 (2H, m), 5.28 - 5.05 (4H, br m), 4.54 - 4.35 (2H, br m), 3.03 (1 H, m), 1.86 (1 H, m), 1.68 (1 H, m), 1.50 (9H, s), 1.49 (1 H, m), 0.82 (3H, d, J =
6.6 Hz) and 0.78 (3H, d, J - 6.5 I-Iz).
STEP B
3R-teri Butoxycarbonyl-5-methyl-2-phthalimidomethyl-hexanoic acid 2-Benzyloxycarbonyl-3R-Pert-butoxycarbonyl-5-methyl-2-phthalimidomethyl-hexanoic acid benzyl ester (26.24. g, 42.8 mmol) was deprotected by catalytic hydrogenolysis in ethanol, according to the method described in Example 32 (Step B). The solvent was removed urnder reduced pressure, the residue was dissolved in toluene (250 ml) and NMM (4.33 g, 42.8 mmol) was added. The mixture was heated under reflux for 2 h. Solvents were evaporated and the remaining oil was dissolved in ethyl acetate and the solution was washed with 5% citric acid (2 x 200 ml,'~ and brine (200 ml), dried over anhydrous magnesium sulphate and filtered. Ths~ solvent was removed, leaving the desired product as a yellow foam (16.58 g, including residual solvent) which was used directly in Step C. ~ H-NMR; 8 (CDC13), 7.83 (2H, m), 7.72 (10H, m), 4.12 (1 H, m), 3.83 (1 H, m), 3.21 (1 H, m), 2.72 (1 H, m), 1.81 - 1.55 (2H, br m), 1.48 (9H, s), 1.31 (1 H, m) and 0.92 (6H, m).
3R-tert-Butoxycarbonyl-5-methyl-2-phthalimidomethyl-hexanoic acid benzyl ester 3R-tent Butoxycarbonyl-5-methyl-2-phthalimidomethyl-hexanoic acid (16.58 g, 42.56 mmol) was dissolved in dry DMF and placed under a blanket of argon. The solution was cooled in an ice bath, benzyl bromide (5.56 ml, 46.82 mmol) and anhydrous sodium carbonate (4.96 g, 46.82 mmol) were added and the mixture was left to stir overnight at room temperature. The solvent was removed under reduced pressure and the residual oil was dissolved in diethyl ether (300 ml) and washed successively with water (2 x 200 ml), 1 M hydrochloric acid (2 x 200 ml) and brine (200 ml). The organic phase was dried (anhydrous magnesium sulphate), filtered and evaporated i:o a crude yellow oil which was purified by column chromatography (silica del, gradient elution, 30-X50% diethyl ether in hexane).
The desired product was isolated as a pale yellow oil (18.2 g, 89%; 3:2 mixture of diastereoisomers). ~H-NMR; 8 (CDC13), 7.78 (2H, m), 7.67 (2H, m), 7.24 (5H, m), 5.05 (2H, m), 4.18 - 4.04 (1 H, br m), 3.81 (1 H, br m), 3.15 (1 H, m), 2.73 (1 H, m), 1.72 - 1.53 (2H, br m), 1.50 (5.4f~, s), 1.41 (3.6H, s) , 1.11 (1 H, m) and 0.90 (6H, m).
T P
3R-Carboxy-5-methyl-2-phthalimidomethyl-hexanoic acid benzyl ester 3R-tent Butoxycarbonyl-5-methyl-2-phthalimidomethyl-hexanoic acid benzyl ester was deprotected by acid~olysis with TFA according to the procedure described in Example 1 (Step G). The product was isolated as a pale yellow oil (16.54 g, including residual solvent) and was used in Step E without further purification. ~ H-NMR; 8 (CDC13, 3:2 mixture of diastereoisomers), 8.28 (1 H, br s), 7.78 (2H, m), 7.68 (2H, m), 7.25 (5H, m), 5.08 (2H, m), 4.15 (1 H, m), 3.89 (1 H, m), 3.25 (1 H, m), 2.88 (1 H, m), 1.82 - 1.52 (2H, br m), 1.25 (1 H, m), and 0.89 (6H, m).
3R-(2,2-Dimethyl-1 S-pyridin-2-ylcarbamoyl-propylcarbamoyl)-5-methyl-2RS-phthalimidomethylhexanoic acid benzyl ester 3R-Carboxy-5-methyl-2-phthalimidomethyl-hexanoic acid benzyl ester was dissolved in ethyl acetate (200 ml), HOBt (5.21 g, 38.58 mmol) and EDC (7.40 g, 38.58 mmol) were added and the reaction mixture was stirred for 3.5 h to ensure complete formation of the activated ester. L-tent Leucine-N-(2-pyridyl)amide (7.32 g, 35.36 mmol) was added and the reaction mixture was heated at reflux overnight.
The solution was cooled before washing successively with 5% aq. sodium bicarbonate, (2 x 200 ml) and water (2 x 200 ml). The organic phase was dried (anhydrous magnesium sulphate), filtered and evaporated under reduced pressure to leave a yellow foam. Column chromatography (silica gel, gradient elution, 20-X50% ethyl acetate in hexane) gave the desired product as an inseparable mixture of diastereoisom~ers (16.89 g, 86%). ~H-NMR; S (CDC13), 9.76 (0.6H, s), 9.58 (0.4H, s), 8.45 (1 H, m), 8.2E~ (1 H, m), 7.85 - 7.60 (5H, br m), 7.23 (4H, m), 7.08 (2H, m), 5.05 (2H, m), 4.7 6 (0.6H, m), 4.57 (0.4H, m), 4.03 (2H, m), 3.33 (0.6H, m), 3.22 (0.4 H, m), 2.85 (0.6H, m), 2.70 (0.4H, m), 1.78 (1 H, m), 1.55 (2H, m), 1.10 (5.5H, s), 1.05 (3.5H, s) and 0.93 - 0.67 (6H, br m).
TEP F:
3R-(2,2-Dimethyl-1 S-pyridin-2-ylcarbamoyl-propylcarbamoyl)-5-methyl-2RS-phthalimidomethylhexanoic acid 3R-(2,2-Dimethyl-1 S-pyriidin-2-yl'carbamoyl-propylcarbamoyl)-5-methyl-2RS-phthalimidomethylhexancric acid benzyl ester (5.08 g, 8.3 mmol) was deprotected by catalytic transfer hydrogenolysis in ethanol, according to the method described in Example 1 (Step E). The product was isolated as a white solid (4.34 g 75%) following solvent evaporation and was used without further purification. ~ H-NMR; b (CD30D, 3:2 mixture of diastereoisomers), 8.31 (1 H, m), 8.08 (1 H, m), 7.81 (5H, m), 7.11 (1 H, m), 4.61 (0.6H, s), 4.52 (0.4H, s), 4.11 (0.6 H, m), 3.99 (0.4H, m), 3.76 (1 H, m), 3.14 - 2.85 (2H, br m)" 1.73 (1 H, m), 1.53 (2H, m), 1.14 (5.5H, s), 1.08 (3.5H, s), 0.92 (3.6H, m) and 0.82 (;?.4H, m).

PC'TIGB95100111 WO 95!19956 T P
3R-(2,2-Dimethyl-1 S-pyridin-2-ylcarbamoyl-propylcarbamoyl)-5-methyl-2RS-phthalimidomethylhexanohydroxamic acid 3R-(2,2-Dimethyl-1 S-pyridin-2-ylcarbamoyl-propylcarbamoyl)-5-methyl-2RS-phthalimidomethylhexanoic acid was converted to the corresponding hydroxamic acid by the method described in Example 32 (Step D). The solvent was removed under reduced pressure and the residue was dissolved in ethyl acetate and washed in 5% aq. sodium hydrogen carbonate, 5% citric acid and brine, dried (anhydrous magnesium ;~ulphate~), filitered and evaporated. The product was purified by column chromatography (acid-washed silica, gradient elution 0-5%
methanol in dichloromethane). Yield: 2.10 g (63%). ~ H-NMR: b ((CD3)2S0, 2:1 mixture of diastereoisomers), 8.42 - 8.15 (2H, br m), 7.65 (5H, m), 6.99 (1 H, m), 4.68 (0.75H, m), 4.55 (0.25H, m), 4.07 (1 H, m), 3.52 (1 H, m), 2.99 - 2.72 (2H, br m), 1.34 - 1.24 (3H, br m), 1.17 (6H, s), 0.95 (3H, s), 0.79 (3H, m) and 0.68 (3H, m).
3R-(2,2-Dimethyl-1 S-(N-oxy-pyridin-2-yl)carbamoyl-propylcarbamoyl)-2S-hydroxy-5-methylhexanohydroxamic acid) O O-H ,~~~ H H
N N N~
. : H O ~ /
HO CONHOH
H

3R-(2,2-Dimethyl-1 S-pyridin-2-ylcarbamoyl-propylcarbamoyl)-2S-hydroxy-5-methylhexanohydroxamic; acid (E=xample 8) (100 mg, 0.25 mmol) was dissolved in dichloromethane (10 ml) and mCPBA (48 mg, 0.28 mmol) was added. The reaction mixture was stirred at room temperature for 3 h, after which TLC
analysis revealed that all of the starting materiavhad been converted to a more polar ferric chloride positive compound. The solvent was removed under reduced pressure and the residue was purified by column chromatography (acid-washed silica gel, 10% methanol in dichloro~methane) to afford the title compound as a glassy solid (60 mg, 58%). m.p. 150 -152°C. ~ H-NMR; 8 ((CD3)2S0), 8.42 - 8.26 (2H, m), 8.19 (1 H, d, J = 7.9 Hz), 7.53 - 7.43 (1 I-i, m), 7.16 - 7.06 (1 H, m), 4.47 (1 H, d, J = 7.8 Hz), 4.02 (1 H, d, J = 6.1 Hz), 2.96 - 2.84 (1 H, m), 1.63 - 1.38 (2H, m), 1.26 -1.07 (1 H, m), 0.99 (9H, s), 0.82 (3H, d, ,J = 6.4 Hz) and 0.75 (3H, d, J = 6.4 Hz). ~3C-NMR;

((CD3)2S0}, 173.7. 170.3, 168.7. 143.2, 137.4. 127.2, 119.5, 114.5, 71.2, 62.1, 47.5, 37.2, 33.6, 26.6, 25.2, 23.6 ~3nd 21.8. IR (KBr diSO); vmax, 3258, 2958, 1652, 1510 and 1430 cm-~ .
BIQLOGICAL EXAMPLE
The following table compares the in vitro potencies of compounds of the present invention against those of similar compounds known in the art where R4 = Me (Comparators 1 to 5).
Comparator 1: 5-Methyl-;3R-(1 S-methylcarbamoyl-2-phenylethylcarbamoyl)-hexanohydroxamic acid.
Comparator 2: 3R-(2,2-Dimethyl-1 S-methyJcarbamoyt-propylcarbamoyl)-2S-hydroxy-5-methylhexanohydroxamic acid.
Comparator 3: 3R-(2,2-Dimethyl-1 S-methylcarbamoyl-propylcarbamoyl)-5-methylhexanohydroxamic acid.

WO 95119956 PCTlGB95/(10111 Comparator 4: 2S-Hydroxy-3R-(1S-methylcarbamoyl-2-phenylethylcarbamoyl)-5-methylhexanohydroxamic acid.
Comparator 5: 2S-Hydroxy-3R-(1 S-methylcarbamoyl-3-methyl-butylcarbamoyl}-5-methylhexanohydraxamic acid.
The potency of compounds of the invention as inhibitors of collagenase was determined by the procedure of Cawston and Barrett, (Anal. iochem., 99, 340-345, 7 979), whereby a 1 mM solution of tree compound being tested, or a dilution thereof, was incubated at 37' for 16 hours with collagen and collagenase (buffered with 25mM Hepes, pH 7.5 containing 5mM CaCl2, O.OS% Brij 35 and 0.02% NaN3). The collagen was acetylated ~4C
collagen prepared by the method of Cawston and Murphy, (Methods in Enzvm,~gy, 80, 711, 1981 ). The samples were centrifuged to sediment undigested collagen, and~an aliquot of the radioactive supernatant removed for assay on a scintillation counter as a measure of hydrolysis. The collagenase activity in the presence of 1 mM of the test compound, or a dilution thereof, was compared to activity in a control devoid of inhibitor and the result reported below as that of inhibitor concentration effecting 50%
inhibition of the collagenase activity (lCSO).
The potency of compounds of the invention as inhibitors of stromelysin was determined by the procedure of Cawston et al, ( i h m~J., 195, 159-165, 1981), whereby a 1 mM solution of the compound being tested, or a dilution thereof, was incubated at 37' for 16~ hours with stromelysin and ~aC acetylate casein {buffered with 25mM Hepes, pH T.S containing 5mM CaCl2, 0.05% Brij 35 and 0.02% NaN3). The casein was acetylated ~4C casein prepared by the method of Cawston et al (ibid}. The stromelysin activity in the presence of 1 mM of the test compound, or a dilution thereof, was compared to activity in a control devoid of inhibitor and the result reported below as that of inhibitor concentration effecting 50% inhibition of the stromelysin activity (lCSq).

WO 95119956 s~ ~ ~ ~ ~ ~ ~ PCT~GB95100111 The potency of compounds of the invention as inhibitors of 72 kDa gelatinase was determined by a procedure basE~d on the method of Sellers et. al, Siochem. J., 171, 493-496 (1979). 72' kDa gE~latinase, derived from RPMI-7951 cells was purified by gelatin-agarose chromatography. The enzyme was activated by incubation with aminophenyl mercuric acetate and approximately 0.05 units was incubated with 50pg [14C;]-radiolabellet gelatin in an appropriate buffer for 16 hours at 37°C. At the end of the incubation 50pg bovine serum albumin, together with trichloroacetic acid (final concentration 16%) were added to stop the reaction and to precipitate any undegraded substrate. The reaction tubes were placed on ice for 15 minutes before centrifugation at 10,OOOg for 15 minutes to sediment the precipitated substrate. A 200p1 aliquot of the reaction supernatant was removed and the radioactivity determined by liquid scintillation counting. The effect of the inhibitors was determined by ref~arence to a dose response curve. The IC5o (the concentration of inhibitor required to cause a 50% decrease in enzyme activity) was obtained by fitting a curve to the data and computing the concentration of inhibitor required to achieve 50°io inhibition of the enzyme. For each ICSo determination, the effect on gelatinase activity of at least 8 concentrations of the inhibitor were examined. The inhibitors were dissolved and diluted in DMSO.

In vitro inhibitory activity IC~o nM

TEST Collagf;nase 72 kDa Stromelysin COMPOUND Gelatinase Example 1 20 60 10 Comparator 1 15 10 350 Example 4 2 5 9 Example 8 I 6 15 30 Example 17 2 30 20 Comparator 2 5 6 200 , Example 2 30 30 15 Example 3 40 30 150 Comparator 3 I 1 ~D 8 700 Example 6 ~ 3~0 8 3 Comparator 4 1.5 3 200 Example 5 30 6 5 Comparator 5 I 8 - 90

Claims (6)

Claims:
1. A compound of formula (I) wherein X is a -CO2H or -CONHOH group;
R1 is hydrogen, methyl, ethyl, hydroxyl, methoxy, allyl, thienylsulphanylmethyl, thienylsulphinylmethyl, thienylsulphonylmethyl or phthalimidomethyl;

R2 is a (C1-C6)alkyl or phenyl(C1-C6)alkyl;
R3 is benzyl, iso-butyl, t-butyl, 1-benzylthio-1-methylethyl, or 1-mercapto-1-methylethyl;

R4 is 3-methoxyphenyl, pyridin-2-yl, pyridin-3-yl, thiazol-2-yl, 4-ethoxycarbonylmethyl-thiazol-2-yl, 5-methyl-1,3,4-thiadiazol-2-yl or 4-tert-butylthiazol-2-yl;
R5 is hydrogen or a (C1-C6)alkyl group;
or a salt thereof, PROVIDED THAT R4 is not 2-pyridyl or 2-thiazolyl when R, is hydrogen, R2 is n-pentyl, R3 is iso-propyl, and R5 is hydrogen.
2. A compound as claimed in claim 1 wherein the stereochemistry is as follows:

C atom carrying the R1 and X groups - S, C atom carrying the R2 group - R, C atom carrying the R3 group - S.
3. A compound as claimed in claim 1 which is selected from the group consisting of:

3R-(2,2-Dimethyl-1S-pyridin-2-ylcarbamoyl-propylcarbamoyl)-5-methyl-2S-propen-2-yl-hexanohydroxamic acid, 3R-(2,2-Dimethyl-1S-pyridin-2-ylcarbamoyl-propylcarbamoyl)-2S-hydroxy-5-methylhexanohydroxamic acid, 3R-(2,2-Dimethyl-1S-(5-methylthiadiazol-2-ylcarbamoyl)-propylcarbamoyl)-2S-hydroxy-5-methylhexanohydroxamic acid, 3R-(2,2-Dimethyl-1S-(3-methoxyphenyl)carbamoyl-propylcarbamoyl)-2S-hydroxy-5-methylhexanohydroxamic acid, 3R-(2,2-Dimethyl-1S-pyrid-3-ylcarbamoyl-propylcarbamoyl)-2S-hydroxy-5-methylhexanohydroxamic acid, 3R-(2,2-Dimethyl-1S-pyridin-2-ylcarbamoyl-propylcarbamoyl)-5-methyl-2S-phthalimidomethylhexanohydroxamic acid, 3R-(2,2-Dimethyl-1S-(thiazol-2-ylcarbamoyl)-propylcarbamoyl)-5-methyl-2S-propen-2-yl-hexanohydroxamic acid, 3R-(2,2-Dimethyl-1S-(thiazol-2-ylcarbamoyl)-propylcarbamoyl)-2S-hydroxy-5-methylhexanohydroxamic acid, 3R-(2,2-Dimethyl-1S-(4-ethoxycarbonylmethylthiazol-2-ylcarbamoyl)-propylcarbamoyl)-2S-hydroxy-5-methylhexanohydroxamic acid, and salts thereof.
4. A compound as claimed in claim 1 which is selected from the group consisting of;

5-Methyl-3R-(2-phenyl-1S-phenylcarbamoyl-ethylcarbamoyl)-hexanohydroxamic acid, 3R-(2,2-Dimethyl-1S-phenylcarbamoyl-propylcarbamoyl)-5-methyl-hexanohydroxamic acid, 3R-(2,2-Dimethyl-1S-pyridin-2-ylcarbamoyl-propylcarbamoyl)-5-methyl-hexanohydroxamic acid, 3R-(2,2-Dimethyl-1S-phenylcarbamoyl-propylcarbamoyl)-2S-hydroxy-5-methylhexanohydroxamic acid, 2S-Hydroxy-3R-(3-methyl-1S-napth-2-ylcarbamoyl-butylcarbamoyl)-5-methyl-hexanohydroxamic acid, 2S-Hydroxy-3R-(3-methyl-1S-(4-methoxyphenyl)carbamoyl-butylcarbamoyl)-5-methyl-hexanohydroxamic acid, 3R-(2,2-Dimethyl-1S-(4-tertbutyl-2,6-dimethylphenyl)carbamoyl-propylcarbamoyl)-2S-hydroxy-5-methylhexanohydroxamic acid, 3R-(2,2-Dimethyl-1S-(4-methoxyphenyl)carbamoyl-propylcarbamoyl)-2S-hydroxy-5-methylhexanohydroxamic acid, 3R-(2,2-Dimethyl-1S-pyrid-4-ylcarbamoyl-propylcarbamoyl)-2S-hydroxy-5-methylhexanohydroxamic acid, 3R-(2,2-Dimethyl-1S-(4-hydroxyphenyl)carbamoyl-propylcarbamoyl)-2S-hydroxy-5-methylhexanohydroxamic acid, 3R-(2-Benzylthio-2-methyl-1S-(pyridin-2-ylcarbamoyl)propylcarbamoyl)-2S-hydroxy-5-methylhexanohydroxamic acid, 3R-(2,2-Dimethyl-1S-phenylcarbamoyl-propylcarbamoyl)-2S-hydroxy-5-phenylhexanohydroxamic acid, 3R-(2,2-Dimethyl-1S-(4,5-dimethylthiazol-2-ylcarbamoyl)-propylcarbamoyl)-2S-hydroxy-5-methylhexanohydroxamic acid, 3R-(2,2-Dimethyl-1S-(5-bromo-thiazol-2-ylcarbamoyl)-propylcarbamoyl)-2S-hydroxy-5-methylhexanohydroxamic acid, 3R-(2,2-Dimethyl-1S-(4-phenyl-thiazol-2-ylcarbamoyl)-propylcarbamoyl)-2S-hydroxy-5-methylhexanohydroxamic acid, 3R-(2,2-Dimethyl-1S-(4-tert-butylthiadiazol-2-ylcarbamoyl)-propylcarbamoyl)-2S-hydroxy-5-methylhexanohydroxamic acid, 3R-(2,2-Dimethyl-1S-phenylcarbamoyl-propylcarbamoyl)-5-methyl-2S-propen-2-yl-hexanohydroxamic acid, 3R-(2,2-Dimethyl-1S-(4-methoxyphenylcarbamoyl)-propylcarbamoyl)-5-methyl-2S-propen-2-yl-hexanohydroxamic acid, 3R-(2-Benzylthio-2-methyl-1S-(pyridin-2-ylcarbamoyl)-propylcarbamoyl)-5-methyl-2S-propen-2-yl-hexanohydroxamic acid, 3R-(2,2-Dimethyl-1S-(pyridin-3-ylcarbamoyl)-propylcarbamoyl)-5-methyl-2S-propen-2-yl-hexanohydroxamic acid, 3R-(2,2-Dimethyl-1S-(4-hydroxyphenylcarbamoyl)-propylcarbamoyl)-5-methyl-2S-propen-2-yl-hexanohydroxamic acid, 3R-(2,2-Dimethyl-1S-(3-methoxyphenylcarbamoyl)-propylcarbamoyl)-5-methyl-2S-propen-2-yl-hexanohydroxamic acid, 3R-(2,2-Dimethyl-1S-(pyridin-4-ylcarbamoyl)-propylcarbamoyl)-5-methyl-2S-propen-2-yl-hexanohydroxamic acid, 3R-(2,2-Dimethyl-1S-(2-methoxyphenylcarbamoyl)-propylcarbamoyl)-5-methyl-2S-thien-2-ylsulfanylmethyl-hexanohydroxamic acid, 3R-(2,2-Dimethyl-1S-(pyridin-2-ylcarbamoyl)-propylcarbamoyl)-5-methyl-2S-thien-2-ylsulfanylmethyl-hexanohydroxamic acid, 3R-(2,2-Dimethyl-1S-(2-methoxyphenylcarbamoyl)-propylcarbamoyl)-5-methyl-2S-thien-2-ylsulfanylmethyl-hexanohydroxamic acid, 3R-(2,2-Dimethyl-1S-(pyridin-2-ylcarbamoyl)-propylcarbamoyl)-5-methyl-2S-thien-2 ylsulfanylmethyl-hexanohydroxamic acid, 3R-(2,2-Dimethyl-1S-phenylcarbamoyl-propylcarbamoyl)-2S-hydroxy-5-phenylhexanoic acid, 3R-(2,2-Dimethyl-1S-(N-oxy-pyridin-2-yl)carbamoyl-propylcarbamoyl)-2S-hydroxy-5-methylhexanohydroxamic acid, and salts thereof.
5. A pharmaceutical or veterinary composition for use in the treatment or prophylaxis of diseases or conditions selected from the group consisting of bone resorption, rheumatoid arthritis, osteoarthritis, periodontitis, gingivitis, corneal ulceration, solid tumor growth and tumour invasion by secondary metastases, neovascular glaucoma, multiple sclerosis, psoriasis, inflammation, fever, caridiovascular effects, haemorrhage, coagulation and acute phase response, cachexia and anorexia, acute infections, shock states, and a graft versus host reactions and autoimmune diseases mediated by MMPs and/or TNF comprising a compound as claimed in claim 1 or claim 2 together with a pharmaceutically or veterinarily acceptable excipient or carrier.
6. A pharmaceutical or veterinary composition as claimed in claim 5 which is for oral use.
CA002181570A 1994-01-20 1995-01-20 Metalloproteinase inhibitors Expired - Fee Related CA2181570C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9401034A GB9401034D0 (en) 1994-01-20 1994-01-20 Metalloproteinase inhibitors
GB9415619.7 1994-08-02
GB9401034.5 1994-08-02
GB9415619A GB9415619D0 (en) 1994-08-02 1994-08-02 Metalloprotease inhibitors
PCT/GB1995/000111 WO1995019956A1 (en) 1994-01-20 1995-01-20 Metalloproteinase inhibitors

Publications (2)

Publication Number Publication Date
CA2181570A1 CA2181570A1 (en) 1995-07-27
CA2181570C true CA2181570C (en) 2006-04-11

Family

ID=36178091

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002181570A Expired - Fee Related CA2181570C (en) 1994-01-20 1995-01-20 Metalloproteinase inhibitors

Country Status (1)

Country Link
CA (1) CA2181570C (en)

Also Published As

Publication number Publication date
CA2181570A1 (en) 1995-07-27

Similar Documents

Publication Publication Date Title
EP0740652B1 (en) Metalloproteinase inhibitors
EP0821668B1 (en) Derivatives of succinamide and their use as metalloproteinase inhibitor
EP0777646B1 (en) Metalloproteinase inhibitors
EP0740655B1 (en) Metalloproteinase inhibitors
AU695507B2 (en) Metalloproteinase inhibitors
EP0873304B1 (en) Metalloproteinase inhibitors
EP0763012B1 (en) Succinyl hydroxamic acid, n-formyl-n-hydroxy amino carboxylic acid and succinic acid amide derivatives as metalloprotease inhibitors
US5919940A (en) Metalloproteinase inhibitors
CA2181570C (en) Metalloproteinase inhibitors
RU2136657C1 (en) Derivatives of hydroxamic or carboxylic acid and pharmaceutical or veterinary composition on said
CA2238275C (en) Metalloproteinase inhibitors
GB2315750A (en) Metalloproteinase inhibitors

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed